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Background 
MatriDerm, a collagen-elastin dermal template, is commonly used in full-thickness wound repair, to 
promote dermal regeneration and improve scar tissue quality. Due to the non-cross-linked status, it is 
expected to biodegrade relatively quickly. Cross-linking the collagen-elastin template could potentially 
enhance its performance. 
 
Aim 
The aim of this study was to investigate the effects of cross-linking on MatriDerm stability, cell 
interaction, biodegradation and wound contraction using established cell culture and murine models.  
 
Method 
MatriDerm was cross-linked with glutaraldehyde vapour and characterized in comparison with non-
cross-linked MatriDerm. Surface morphology, in-vitro stability and strength were assessed through 
scanning electron microscopy, measurement of protein loss, and tensile modulus testing, 
respectively. Cell-scaffold interaction, cell proliferation and migration was examined using cultured 
human dermal fibroblasts. The scaffold biodegradation and its impact on wound healing and 
contraction was studied in a murine model.  
 
Results 
Cross-linked MatriDerm displayed a slight but significant reduction in average pore size, a significant 
reduction of total protein loss and a 3-fold increase in tensile strength compared to the non-cross-
linked template. In-vitro studies observed a significant increase of fibroblast proliferation and migration 
in cross-linked MatriDerm and reduced scaffold contraction compared to non-cross-linked MatriDerm. 
In the murine model, non-cross-linked MatriDerm was almost completely biodegraded after 14 days 
but cross-linked MatriDerm remained intact, demonstrating similar host responses. 
 
Conclusion  
Cross-linked MatriDerm’s durability was enhanced, demonstrated by significant increase in biostability 
and strength both in-vitro and in-vivo. The extended exposure of cross-linked MatriDerm in a wound 
could have beneficial effects on scar tissue formation and further its potential as a base for skin tissue 
engineering.  
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Chapter 1A. Introduction 
 
According to the WHO, approximately, 11 million people worldwide required medical 
treatment for burn injury in 2014.[1] Burn injury occur in people of all ages, 
nationalities and social background, on the basis of a wide variety of mechanisms. 
Affecting such a large group of individuals, burn injury management has taken up an 
area in the medical field with specialised expertise. At present, the field of burns 
management is transitioning from mortality and survival to scar management and 
quality of life. In 1900’s, it was very unlikely for a patient with a severe, large burns, 
>50% total body surface area (TBSA) to survive. In 1952, only half of the paediatric 
patient population with a burn injury over 50% TBSA survived.[2]  If a patient 
survived the first critical 48 hours following burn injury, the subsequent likelihood of 
infection that followed within 5 days of injury led to another clinical challenge, battling 
high mortality as patients succumbed to invasive blood stream and wound infections. 
The quest to survive the injury lead the major advances in burn injury and infective 
complications including advances in understanding the pathophysiology, improving 
fluid resuscitation, early excision of burn injury and wound closure, infection control 
using silver, hypermetabolic and nutritional support and strict physical and 
occupational therapy.[2, 3] As a result of the advances in the fields of acute care and 
infectious disease, most patients today survive any type of burn. Infection remains a 
major challenge but advanced antimicrobial and antibiotics regimes have led to 
increased survival.[4] This has allowed a shift in attention to the management of the 
long-term burn injury outcome. With increased survival, many burn injury 
consequences have become apparent, predominately related to the physical and 
psychological consequences of disfiguring scarring. Whilst psychological issues 
present an ongoing social challenge, of major concern is scar care and 
management, additionally contributing to the psychological challenge.[5-7] The focus 
of attention has therefore been directed to both the prevention and management of 
burns scarring, increasing the scope of scar prevention and management options. 
For further introduction into current challenges in burn management, please see 
chapter 1B. 
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Scarring has been identified as a major consequence of split thickness skin 
grafting.[8] As part of the mainstay treatment of full-thickness burns, split skin 
thickness grafting plays an essential role.[9] Human skin heals by re-epithelization 
from wound edges and from progenitors cells of dermal components, such as hair 
follicles.[10] An intact dermis is essential for the re-epithelization process, as it 
functions as both the origin of the epithelial cells and as support for the migration of 
cells from wound edges to close the wound.[11] Physiologically, dermis is a complex, 
3-dimensional structure, based on an extracellular matrix predominately made of 
collagen and elastin, supporting different cell types, endovascular plexuses and 
appendages such as hair follicles and sweat glands. In full-thickness wounds or 
burns, the dermis is permanently damaged and cannot regenerate to allow for re-
epithelialization.[11] The gold standard for treatment of these defects therefore is to 
remove the damaged dermis to leave a well-vascularized wound bed by surgical 
debridement and to cover the fresh wound with an autograft.[9] The autograft is a 
split thickness skin graft with intact epidermis and small areas of dermis from its 
donor site. The autografted area heals as small areas of dermis are transplanted 
with a healthy epidermis to a well-vascularised wound bed and the donor site heals 
as it contains a largely intact dermis, allowing for re-epithelization. But due to the 
lack of a healthy, fully intact dermis on the recipient wound, scarring is a common 
outcome.[8, 11] The understanding of this problem initiated the idea of developing a 
neodermis, the starting point of investigating into skin recovery in the 1970s.[12]  
 
The first artificial dermis was developed by Yannas and Burke in 1980, opening the 
door for bioengineered regeneration of a neodermis.[13-15] Integra is a collagen 
dermal template, cross-linked with glutaraldehyde, still available today and often 
used in clinical practice. In 1988, the first clinical trials were successful in treating 
small, full-thickness wounds.[16, 17] Triggered by its success, the next decades 
were filled with the development and introduction of a wide range of skin 
substitutes.[12] Skin substitutes are now commercially available, ranging in porous 
protein constructions with a variety of components ranging from natural biomaterials 
to synthetic or a combination of both.[8, 12, 18, 19] For further introduction of skin 
substitutes, please see ‘2.2 Skin substitutes’ in chapter 1B. 
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Despite the wide range of skin substitutes that are available, skin tissue engineering 
is an ongoing developing biotechnological field. By combining bioengineered 
matrixes with natural skin components such as autologous or allogeneic skin cell 
types, growth factors to promote wound healing or vascularization, or common 
appendages found in the physiological dermis, skin tissue engineering is becoming a 
reality in the foreseeable future.[20] However, limitations are being identified, many 
due to the simplicity of the current substitutes.[21] As explained earlier, human skin 
is a complex structure with a dynamic nature. Many of the current skin substitutes 
today, are not able to reproduce that complexity.[22] This has been the impetus for 
further innovation in biomaterials and development in complexity of skin substitutes. 
Elastin has been an important step in increasing scaffold complexity.[23] As a natural 
component of human skin, making up 2-4% of the dry weight of the extracellular 
matrix and playing an essential role in mechanical structure and cell-signaling, 
elastin has been added into dermal templates.[24] The now commercially available 
dermal template containing both collagen and elastin is marketed as MatriDerm. The 
importance of elastin has become evident with the advances in the knowledge of 
scar tissue formation, showing its effect on a microscopic, macroscopic and clinical 
level. Elastin has shown to have a positive effect on myofibroblast differentiation [25], 
the main contributor to wound contraction, and increase native elastin 
production.[26] It is expected that the introduction of elastin in dermal templates will 
increase scar pliability, creating a more natural scar.[23]  
 
However, there are still major limitations of the collagen-elastin dermal template 
present. Whilst MatriDerm compares more closely to skin’s physiological 
extracellular matrix than other dermal templates, it is expected to biodegrade in-vivo 
relatively quickly. The fibres in MatriDerm are not further stabilised via chemical 
cross-linking, unlike many other dermal substitutes, such as Integra. Some studies 
comparing different commercially available templates have indicated its relatively 
fast biodegradation rate in animal models.[27, 28] The scaffold will biodegrade 
quicker if the scaffold structure is mechanically weak, affecting the full regeneration 
of skin tissue. Detailed analysis of the collagen-elastin template and further 
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development in these small steps will not only strengthen the role of this particular 
dermal template but add to the developing knowledge of skin tissue engineering, 
possibly contributing to further understanding of the wound healing process and scar 
tissue formation. For further introduction into the innovations of skin substitutes and 
elastin, please see ‘6. Skin tissue engineering in the treatment of burn injury’.    
 
The aim of this thesis is to contribute to the advances in skin tissue engineering by 
identifying one of the limitations of these increasingly complex structures and 
attempting to overcome it. Chemically cross-linking a collagen-elastin matrix will aid 
a future step in the development of clinically relevant advancements in skin tissue 
engineering. With this step, this study aims to not only improve the quality of skin 
substitutes but add to the vast knowledge of a growing field, contributing to 
strengthening the role of bioengineered regeneration further.  
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Severe burn injuries are the most traumatic and physically debilitating injuries affecting nearly every organ system
and leading to significantmorbidity andmortality. Early burnwound excision and skin grafting are common clinical
practices that have significantly improved the outcomes for severe burn injured patients by reducing mortality rate
and days of hospital stay. However, slow wound healing, infection, pain, and hypertrophic scarring continue to re-
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1. Introduction
Severe burn injuries are the most traumatic and physically debilitat-
ing injuries affecting nearly every organ system and leading to signifi-
cant morbidity and mortality. In Australia, over 10,000 people are
hospitalised each year because of severe burn or scald injuries. According
to theWorldHealth Organisation (WHO), 180,000 deaths annually are re-
lated to burn injury and in 2004, nearly 11million peopleworldwidewere
severely burned and required medical treatment [1]. Both small burn and
large severe burn injuries initiate the wound healing process which con-
sists of several highly integrated and overlapping phases: inflammation,
cell recruitment, matrix deposition, epithelialization and tissue remodel-
ling. In additional to local wound repair, severe large burns also stimulate
a persistent pathophysiological stress response and a systemic hypermet-
abolic-catabolic condition. These pathophysiological changes have great
effects on the pharmacokinetics and pharmacodynamics of drug use in
the treatment of severe burn injuries. Early burn wound excision and
skin grafting are common clinical practices that have significantly im-
proved the outcomes for severe burn patients by reducing mortality rate
and days of hospital stay [2]. However, slow wound healing, infection,
pain, and hypertrophic scarring continue to remain as major challenges
in burn management and research. In the present article, we discuss the
challenges, advances and novel strategies in burn management and re-
search with a focus on burn wound infection, pain management, treat-
ments of scarring and skin tissue engineering.
2. Clinical practice in the treatment of burn injury
2.1. Skin grafting
When burns or scald injuries are deep partial-thickness in the der-
mis or completely destroy all skin layers, wounds cannot be closed by
Advanced Drug Delivery Reviews xxx (2017) xxx–xxx
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the primary healing process or by suturing [3], rather additional surgical
procedures are required. The gold-standard treatment for partial- and
full-thickness burn injuries is early excision of necrotic tissue followed
by autologous skin grafting (Fig. 1). Skin grafting involves the transplan-
tation of healthy skin from an undamaged donor site of the patient to
the wound site. Autologous skin grafts can be full thickness, consisting
of epidermis and dermis, or split-thickness, consisting of the epidermis
and upper part of the dermis. Unfortunately, in practice, donor skin is
extremely limited for patients with severe burn injury N50% total
body surface area (TBSA) [4,5]. This problem can be overcome by re-
peated harvesting of the donor sites over a period of time. However,
healing of donor sites can be slowwith additional scarring and possible
pigmentation disorder [6,7].While autografts can bemeshed to increase
the available surface area of the graft up to four times, themeshing pro-
cess compromises the quality of the original graft and the recipient
area heals with an irregular meshed pattern [8] and can result in severe
scarring [9].
2.2. Skin substitutes
Skin substitutes could protect large burnwoundswhen donor skin is
limited, to enhance wound healing, increase the dermal component of
healedwound, reduce inflammatory responses and subsequent scarring
[10–13]. Since 2000, over 30 new skin substitutes have been tested or
used in the treatment of burn injuries (Table 1). Skin substitutes can
be categorized into biological substitutes, synthetic substitutes or a
combination of both. Biological substitutes can be further categorized
into 1) natural scaffolds such as Alloderm, an intact, de-cellurised and
dermal human matrix, 2) constructed scaffolds such as Integra, com-
posed of lyophilized collagen, supplemented and cross-linked, or 3) cul-
tured scaffolds, such as cultured epithelial graft, autologous cultured
fibroblasts and keratinocytes. Biological skin substitutes have compo-
nents that resemble natural skin, yet these skin substitutes are relatively
simple compared to the complexities of human skin. The majority of
skin substitutes available for clinical practice contain allogenic biological
products, and the risk of disease transmission poses as a limitation par-
ticularly for natural biological skin substitutes. Despite extensive and
strict sterilization procedures, currentmethods are insufficient to certify
biological skin substitutes to be free of any unknown diseases or prion
diseases from animal material, such as Creutzefled-Jakob disease [14].
Furthermore, there is evidence to suggest that allogeneic skin is highly
immunogenic and that cellular remnants in the extracellular matrices
(ECM) may be responsible for reduced skin graft take or even rejection
[9]. Human derived allogenic skin is further limited by its supply. Autol-
ogous biomaterials have the advantage of culturing cells for a large sur-
face area from a small skin biopsy, however culturing cells is time
consuming and may comprise wound healing [15,16].
In contrast to biological substitutes, synthetic substitutes are free
from any risk of disease transmission. However, only a few synthetic
skin substitutes are on the market today. Although synthetic materials
have greater structural integrity compared to natural products, its
poor bioactivity remains amajor concern [17]. In addition, poor host re-
sponse may lead to negative effects on scar quality. Despite limitations
in materials and cost, the development of bio-engineered skin is in-
creasing due to innovative possibilities with new techniques and bio-
materials, providing a glimpse into a promising future. These steps
have promoted a shift in focus from traditional surgical interventions
to skin tissue-engineered regeneration.
2.3. Wound dressings
Wound dressings are developed for wound coverage to aid re-epi-
thelialization, prevent wound infection, skin desiccation, and further
skin damage. Wound dressings can be categorized into four groups: bi-
ological dressings; conventional dressings; biosynthetic dressings and
antimicrobial dressings. Biological dressings include cadaver allograft
skin (transplantation between individuals of the same species), xeno-
graft (transplantation between individuals of different species) and
human amnion,which have been adopted to temporarily cover wounds
for reepithelization. Although biological dressings are effective in
terms of improving the quality of wounds for further skin grafting,
they cannot be used as a permanent skin replacement due to immuno-
logical disparities [8]. Furthermore, many issues are associated with
biological dressings, such as inconsistent quality, limited supply, and
the risk of pathogen transfer [44]. Conventional dressings which do
not contain antibiotics or medications, e.g. Vaseline gauze or silicone
sheets are also widely used to temporarily cover wounds during
reepithelialisation. However, these dressing tend to adhere to the
Fig. 1. Autologous skin grafting: (A) partial-thickness skin graft taken from the healthy donor site. (B) Skin graft is meshed to increase the surface area (C) Application of skin graft on the
wound bed.
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wound surface and their need for frequent changes traumatizes the
newly epithelialized surface and delays healing [45,46]. Biosynthetic
dressings are designed to use materials that mimic the function of skin
by replacing the epidermis or dermis, or both. Examples include
Biobrane® and TransCyte®. Antimicrobial dressings are widely used
in burn management to prevent wound infection, by minimising bacte-
rial colonisation. A number of antimicrobial dressings have been intro-
duced to burn care. These products can contain either silver (e.g.
Aquacel AG), nano-crystalline silver (e.g. ACTICOAT), cadexomer iodine
(e.g. Iodosrob), or honey as antimicrobials. Application of silver com-
pounds on burn wounds was a majormilestone in topical burn therapy,
which remarkably reduced the incidence of burn wound induced sepsis
and death.
2.4. Negative pressure wound therapy (NPWT)
Negative pressure wound therapy (NPWT; also known as vacuum
assisted closure, topical negative pressure therapy ormicrodeformational
wound therapy) is currently utilised in wound care for both large and
small burns. It was first demonstrated to be effective at halting partial
thickness wound progression compared to most other pharmacological
means available [47,48]. NPWT was further utilised as part of temporary
abdominal closure in acute burn patients or in a high risk burns patient
who underwent pre-operative optimisation prior to skin grafting [49,
50]. Considering burn injury as the most traumatic and composite
wounds, the use of NPWT has been acknowledged to be helpful by
allowing surgical teams to effectively manage acute burns, as well as
their chronic sequelae. Numerous case reports have been published
supporting the ability of NPWT to improve both split thickness or full
thickness skin graft take, allowing early mobilisation of patients [51–
55]. Additionally, this effect has been demonstrated both in the acute set-
ting and when excising burn scar contractures [54,56–58].
The use of NPWT with skin substitutes or templates, such as
Integra® has been utilised in clinical practice to improve poor skin
graft take and infection [59,60], as NPWT has been hypothesized to pre-
vent shear. Additionally, the optimised NPWT environment is thought
to contribute to accelerated wound healing [61–63]. More studies
have also shown that NPWT can also be effective to promote wound
healing using Matriderm® or Pelnac® skin substitute with split skin
graft [64,65]. The positive outcomes of NPWT associated with improved
graft and dermal substitute take in burn injury has been attributed to re-
ducedwound infection [54,66–68]. A case control study demonstrated a
significantly reduced number of infections in theNPWT treatment com-
pared to normal therapy [68]. Additionally, a study using a porcine burn
model with locally applied Pseudomonas aeruginosa infection [69] found
that NPWT effectively reduced bacterial proliferation and alleviated
sepsis progression compared to usual wound treatment. Cytokine anal-
ysis and histopathological examinations confirmed that NPWT reduces
wound inflammation and infection.
Recent evolutions in NPWT involve combining use with instillation
or continuous irrigation. NPWT instillation (NPWTi) is a cyclical process
whereby a solution of choice is instilled into a wound covered by NPWT
dressings. Comparatively, NPWT continuous irrigation (NPWTci) is
non-cyclical. This method involves the continuous irrigation of solution
into the foam and wound bed, while the suction action of NPWT is con-
tinuously applied at the same time. Although, there are no clinical case
reports on NPWTi and NPWTci systems in burn injury, these advanced
systems could play a beneficial role in future burn woundmanagement
Table 1
Skin substitutes used in burn care.
Skin substitute Composition Cells incorporated
KaroSkin
[18]
Human cadaver skin with dermal and epidermal cells
GraftJacket®
[18,19]
Human acellular pre-meshed dermis
StrataGraft™
[20]
Human dermal fibroblasts and stratified epidermis derived from Near-diploid Immortalised
Keratinocyte S (NIKS)
GlyaDerm®
[21,22]
Glycerol preserved acellular dermal collagen-elastin matrix
OASIS® Wound Matrix
[23]
Porcine acellular lyophilized small intestinal collagen matrix
XenoDerm
[24,25]
Lyophilised acellular porcine dermis
Permacol™
[26]
Porcine acellular diisocyanite cross-linked dermis
PermaDerm™
[27,28]
Autologous keratinocytes and fibroblasts cultured with bovine collagen
OrCel®
[29]
Bilayered type I collagen matrix Allogenic neonatal foreskin keratinocytes and
fibroblasts
RenoSkin®
[30]
Bilayer dermal matrix – silicone film and porous crosslinked bovine collagen
TransCyte®
[31,32]
Porcine collagen-coated nylon mesh Allogenic neonatal human foreskin fibroblasts
Integra®
[33–35]
Cross-linked bovine tendon collagen and glycosaminoglycan, and polysiloxane (silicone)
Pelnac®
[36,37]
Porcine tendon derived atelocolla
gen type I, sponge layer with silicone film
Hyalograft 3D
[23]
Hyaluronic acid membrane Autologous fibroblasts
Dermagraft®
[38]
Bioabsorbable polygalactin mesh matrix Human neonatal fibroblasts
TissueTech Autograft
System
[18]
Microperforated
hyaluronic acid membrane
Autologous keratinocytes and fibroblasts
Suprathel®
[39–42]
Synthetic copolymer – dl-lactide (N70%), trimethylenecarbonate and ε-caprolactone
Laserskin®
[43]
Hyaluronic acid membrane Autologous keratinocytes and fibroblasts
MySkin™
[18,28]
Silicone support with a specially formulated surface coating Autologous keratinocytes
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via reducing number of treatment days, accelerated clearance of infec-
tion and wound closure [70]. A study assessing NPWTi suggested that
NPWTi may promote wound granulation rates compared to normal
NPWT [71]. When antimicrobial solutions were used in conjunction
with NPWTi, a lower bioburden load was found when compared to
standard dressings soaked with the same antimicrobial solution. This
finding suggests that NPWTi has the potential to increase the efficacy
of the antimicrobial solutions in burn care.
3. Burn wound infection: challenges and innovations
Wound infection is a major challenge in burn care and is the most
common cause of mortality after burn injury [72–74]. Pathogens have
evolved overtime in line with innovations and antibiotic use [75]. Cur-
rently, multi-drug resistant (MDR) organisms and fungi present a
major challenge [76]. With limited new antibiotics [77] innovations en-
hancing the effectiveness of currently available topical and systemic an-
timicrobials is paramount to improve morbidity and mortality in burn
patients.
Bacterial organisms causing burn wound infection can be classified
into two groups, gram negative and gram positive (Table 2). Gram neg-
ative bacteria causemost burnwound infections, with similar incidence,
prevalence and pathogens regardless of geography or institution [78,
79]. Burn wound infection by Pseudomonas aeruginosa, Klebsiella pneu-
monia and Escherchia coli and the gram positive organism Staphylococ-
cus aureus are independent predictors of mortality [72]. Staphylococcus
aureus is the major cause of gram-positive burn wound infections glob-
ally [74] and a common cause of septicaemia [76,80]. Methacillin resis-
tant Staphylococcus aureus (MRSA) is now the major pathogen in some
burn centres [74] and vancomycin resistant enterococci (VRE) although
not as common, appears to be highly virulent [74].
3.1. Topical antimicrobial agents
Topical application of antimicrobial agents began with the applica-
tion of sulfathiazole dressing to burns in 1940's [81].With the discovery
of the antibacterial properties of silver [82], silver sulfadiazine dressings
have been the standard of care since 1968 [83]. Recent systematic re-
views and meta-analysis report silver sulfadiazine to have poorer
healing outcomes and little evidence of effectiveness in preventing
wound infection than alternate dressings [84,85]. Mechanisms believed
to be responsible for these outcomes are the requirement for regular
wound dressing changes, poor eschar penetration and cytotoxicity of
silver to keratinocytes and fibroblasts delaying wound healing [85–
87]. A further issue is the recent report of resistance to silver in clinical
isolates [88].
Numerous innovative approaches have then been investigated in the
past decade to achieve alternate topical antimicrobial treatment for
burn wounds which do not compromised wound healing, require less
dressing changes and induceminimal antibiotic resistance (Table 3). In-
novations generally involvenewmethods of deliveringwell-established
antibiotics, alternative antimicrobials such as curcumin [89,90] or syn-
thetic antimicrobial agents such as LLKKK18 [91], an antimicrobial pep-
tide. Clinical trials comparingnovel dressings containing LLKKK18 to the
silver dressings in human burn cohortswill likely challenge convention-
al practice in the near future. Further investigation of the effectiveness
of novel dressings against MDR bacteria is also required.
3.2. Systemic antibiotics
Overtime treatment with various systemic antibiotics have propa-
gated the evolution of micro-organisms causing morbidity and mortal-
ity in burns [76]. Currently, drug resistant organisms pose a difficult
challenge. MRSA is the most common resistant organism encountered
in burns and is normally treated with an ancient antibiotic, vancomycin
[76,92]. Despite various measures to control and treatMRSA, the organ-
ism has continued to evolve with vancomycin-intermediate susceptible
Staphylococcus aureus (VISA), a developing strain. New antimicrobials
including oxazolidiones, streptogramins, tigecycline, daptomycin,
dalbavancin [74,76] remain an important addition to the antibiotic ar-
mamentarium to combat such infections [93].
Inmanyburn centers, the predominant organisms are the gramneg-
ative pathogens Pseudomonas aeruginosa and Acinetobacter baumanni
[76,78,79]. Resistance of these organisms to antibiotics, including re-
serve antibiotics such as the carbopenams [76], has seen increasing reli-
ance on the use of old antibiotics [74]. Colistin, a polymyxin antibiotic,
was once abandoned due to extensive side effects (neurotoxicity and
nephrotoxicity) but has recently been reinvigorated to combat MDR
gram-negative organisms [94]. This new reliance on colistin has trig-
gered various efforts to redevelop and re-engineer the antibiotic [94].
One such effort is theutilisation of nano-antibiotic polymer therapeutics
inwhich colistin is conjugated to dextrin. The dextrin-colistin conjugate
exploits the enhanced permeability and retention effect (EPE) [95] en-
abling the molecule to be delivered preferentially to burn wounds and
in a greater concentration for a prolonged duration with less systemic
side effects. Pre-clinical studies establishing antimicrobial spectrum,
pharmacodynamics and pharmacokinetic properties in an animal
model have shown a reduced toxicity profile with favourable pharma-
cological properties [96,97].
Efforts to improve drug delivery of current antibiotics also offers
promise. Critically illness patients post severe burn injuries have sub-
stantially altered physiology, which may profoundly lower antibiotic
tissue concentrations culminating in therapeutic failure and the emer-
gence of resistance. Physiological changes include altered fluid balance,
a hyperdynamic circulation, renal and hepatic dysfunction and organ
support [98]. Methods to improve drug delivery involve regular moni-
toring of antibiotic concentrations and the delivery of antibiotics via
continuous infusion rather than bolus regimes [99]. For example a re-
cent study demonstrated improved outcomeswhen P. aeruginosa infec-
tion was treated via extended infusions of pipercillin-tazobactem [100].
3.3. Anti-fungal infection
The incidence of fungal infections is increasing [101–103] with can-
dida species being the most common [104]. In the USA, fungi are re-
sponsible for approximately two thirds of invasive burn wound
infections [75] and is the fourth most common organism isolated in
blood cultures [104]. Fungal infections, particularly non-candida infec-
tions such as Aspergillus spp. and moulds are associated with high mor-
tality due to sepsis with multi-organ failure [76]. Clinically, fungal
infection has an added comorbid effect equivalent to an additional
burn involving 33% of the total body surface [105]. The most effective
Table 2
Common pathogens causing burn wound infection.
Group Species Antibiotic treatment
Gram negative Psuedomonas aeruginosa Pipercillin-tazobactam
Actinetobacter baumanni Carbapenems
Enterobacteriaceae Cephalosporins
Gram positive Staphylococcus aureus Penicillins
Streptococcus Penicillins
Enterococcus Penicillins
Fungi Candida spp. Amphotericin B,
Micafungin
Non-albicans Candida Amphotericin B
Aspergillus Caspofungin
Blastomycosis Fluconazole
Viruses Herpes simplex Acyclovir
Varicella-zoster Acyclovir
Drug resistant strains MRSA Vancomycin
VRE Linezolid
(Extended-spectrum
beta-lactamases) ESBL
Carnbapenems
MDR P. aeruginosa Colistin
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treatment for fungal infection is prevention via removal of burned tissue
and closure of wounds [74]. Positive fungal wound cultures and
fungaemia particularly if Aspergillus spp. or other moulds are cultured,
are generally indications for systemic therapy although specific indica-
tions for treatment remain unclear [103]. Currently three classes of sys-
temic antifungal drugs are available for treating fungal burn wound
infection, including polyenes, azoles and echinocandins [104].
Polyenes such as amphotericin B are first line agents for the treat-
ment of Candida, but its use is often limited by significant nephrotoxici-
ty [74,76,104]. Lipid soluble formulations of amphotericin B although
causing less side effects, are substantially expensive [104]. Of the azoles,
fluconazole is the empiric choice for invasive candidiasis, although de-
veloping resistance is an issue [104]. Echinocandins the newest antifun-
gal agent introduced in 2001, are effective with a unique mechanism of
action inhibiting the synthesis of β-1,3-D-glucan polymers and has a
more favourable toxicity profile and pharmacokinetics [76,104,106].
Aswith antibiotics, future research addressing the impact of burn injury
induced physiological alterations on the pharmacokinetic profile of sys-
temic antifungal therapies has yet to be elucidated.
Pathogens causing morbidity and mortality in burn wounds contin-
ue to evolve in response to dynamic pressure from antibiotic use. Future
clinical application of novel antimicrobial wound dressings in place of
the established silver dressings is promising. Systemically, challenges
include enhancing the effect of current antibiotics through the pursuit
of individualized dosing regimenswhich adjust for in altered physiology
after burnwound, and the utilisation of the EPE to enhance systemic de-
livery are encouraging innovations. Fungal pathogens are emerging as
more common and troublesome infections, continued development
and enhanced understanding of the clinical use of antifungal drugs
will benefit burns patients.
4. Burn pain management: challenges and innovations
Control of burn pain is central to the recovery and reintegration of
burn injury patients. Poor control of pain can hamper the healing pro-
cess due to fear and anxiety induced elevation of stress hormones
(such as glucocorticoids). This can lead to long lasting physical and psy-
chological burdens and hospital stay. Three mechanisms are counted to
burn pain– nociceptive, neuropathic and inflammatory. Intravenous
morphine forms the basis of pain management through early stage
post-burn injury, while shorter half-life opioids and nerve blockers are
alternative options. During the wound healing process, surgical
wound debridement, physiotherapy and dressing changes increase
pain levels substantially. Nociceptive pain levels decline as scars mature
and physical therapy continues. Additionally, neuropathic type pain
may increase at this stage along with pregabalin, gabapentin used for
treatment of painful neuropathy.
4.1. Issues of pain management
Post severe burn injury at 48 h, a hypermetabolic response begins
which is known to effect on drug clearance rates, pharmacokinetics
(PK) and pharmacodynamics (PD). However, lack of literature has
been reported on the effect of burn-induced hypermetabolism on drug
PK and PD [107,108]. As a result, appropriate dosing for a majority of
drugs used in burn pain remains an area requiring further investigation.
Opioid reliance continues to define burn pain care [109]. The side ef-
fects of opioid use include: nausea, vomiting, constipation, gastrointes-
tinal dysmotility, dependence and tolerance. Severity of burn pain
and duration of treatment also predisposes to tolerance, escalation of
doses and high risk of addiction. Moreover, opioid can induce
hyperalgesia, an additional overarching state of enhanced pain sensitiv-
ity along with increasing doses of opioid [110]. Issues of opioid induced
hyperalgesia presents a clinical challenge in the burn injury population
[110]. In consideration of these effects, further investigation of opioid
treatment options, alternatives, and adjuncts is paramount for burn pa-
tient care.
4.2. Treatments for burn pain
4.2.1. Ketamine
Ketamine forms a part of burn painmanagement for a number of de-
cades, playing a major role in burns procedures since the 1960's due to
potent analgesic, sedative and amnesic properties [111–113]. Recent lit-
erature exhibited the capability of ketamine to reduce primary and sec-
ondary hyperalgesia; while also increasing thermal injury induced
mechanical pain thresholds [114,115]. Delivery of ketamine in burns pa-
tients can be conducted by intravenous (IV) infusion, intravenous pa-
tient-controlled analgesia (IV-PCA), intramuscular, oral and intranasal
administration [116–120]. Studies examining the combination of keta-
mine with other classes of burn-pain pharmacology have been promi-
nent, particularly in an effort to reduce sympathomimetic, sedative
and psychomimetic side effects. Ketaminewasfirst combinedwith ben-
zodiazepines in attempt to reduce these adverse effects [121]. A study
reported the positive effects of this combination in burns patients, indi-
cating that ketamine in combination with midazolam successfully
reduces the side effects of ketamine [120]. Further study provided evi-
dence that combination of ketaminewith propofol can be used to atten-
uate ketamine's unexpected effects [122]. The range of pharmaceutics
utilised in burn pain management provides opportunity to further
Table 3
A summary of studies in topical antimicrobials.
Studies Antimicrobial Delivery system Organisms tested Year
1 Ciprofloxacin Keratin hydrogel S. aureus, Psuedomonas 2016
2 Gentamicin Soy protein films Psuedomonas 2015
3 Curcumin Gel-core hyaluosomes Nil 2015
4 Curcumin Nanoparticle incapsulation MRSA, Psuedomonas 2015
5 LLKKK18 Carbopol® hydrogel Nil 2015
6 Gentamicin Hybrid bi-layer wound dressing Psuedomonas 2015
7 Nitric oxide Polymeric film Acinetobacter baumanii 2014
8 Mupirocin Liposomes in hydrogel S. aureus 2013
9 Gentamicin Polyglyconate mesh and PDLGA matrix Psuedomonas 2011
10 Lysostaphin Chitosan-collagen hydrogel MRSA 2011
11 Fucoidan-chitosan Hydrogel Nil 2008
12 Minocyclin Chitosan film and tegaderm Nil 2007
13 Chlorhexidine Bilayered hydrogel and chitosan foam S. aureus, Psuedomonas 2000
14 Amphotericin B Nanoparticle hydrogel Candida spp. 2014
15 Boron/pluronic copolymers Carbopol-based hydrogel Bacteria, yeast, fungi 2015
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investigate ketamine synergism, particularly in the areas of background
and breakthrough pain which have not be studied in previous research.
4.2.2. Sedatives and anxiolytics
Benzodiazepines have no analgesic properties but are extensively
utilised in burns patients as adjuncts for pain management. It has
been shown in recent burns pain studies that anxiety decreases pain tol-
erance and increases use of pain medications [123,124]. Recent studies
exploring benzodiazepines in burns patients have largely centered on
combination with other sedatives (such as ketamine and dexametha-
sone). α2-agonists, similar to benzodiazepines, are used as sedatives
and anxiolytics in burns. A clinical trial study of α2-agonists indicated
the potential for an additional role in pain reduction. However, this
must be in consideration ofα2-agonist side effects; reduced sympathet-
ic outflow and hypotension, which have complicated several burn stud-
ies to date [125,126].
4.2.3. Neuropathic drugs and pruritus
Pregabalin and gabapentin are anticonvulsants used in the treat-
ment of neuropathic pain of burn injury patients. A case series in 2010
established the efficacy of pregabalin in reducingpost-burn neuropathic
pain scores of outpatients [127]. Subsequent randomised controlled
trial demonstrated the role of pregabalin in both the acute and healing
phases of burn injury [128,129], demonstrating reductions of neuro-
pathic pain during the first four weeks of treatment, while additionally
reducing pain levels during procedural pain events. Another study
found that pregablin had positive effects in reducing post-burn pruritus,
suggesting that pregabalin can be used in any patient with moderate to
severe pruritus [128]. Secondary to this, recommendation was made to
utilise pregabalin in mild itch to achieve the benefit of rapid and com-
plete response.
Gabapentin has also received attention from burn pain investigators.
Regarding to the acute setting, conflicting evidence has arisen on the ef-
ficacy of gabapentin in reducing acute burn pain and opioid consump-
tion. Studies have shown positive results with gabapentin via
reduction of mechanical allodynia in experimental partial thickness
wounds [130,131]. However, a randomised controlled trial study dem-
onstrated that burn patients receiving gabapentin on day 1 of injury
did not display any significant effects on either opioid consumption or
acute burn pain [132]. This work is supported by a double-blinded, pla-
cebo-controlled, crossover study, showing no anti-hyperalgesic or opi-
oid enhancing effects when gabapentin was used in an experimental
superficial burn model [133]. Similar to pregabalin, gabapentin shows
favourable results in the management of post-burn pruritus. Successful
use of gabapentin in paediatric burns patients was reported as an alter-
native to antihistamines [134]. Subsequent studies further established
gabapentin as a more effective alternative to antihistamine as mono-
therapy. Additionally, gabapentin was demonstrated as a first line ther-
apy that leads to greater efficacy at each step up in therapy as part of a
burns pruritus protocol. Other notable pharmacological forms of anti-
pruritic therapy include naltrexone, ondansetron and botulinum toxin
[135–138]. However, these are lacking substantial evidence and require
further investigation in burns populations.
4.3. Future pain targets and considerations
Advances in pain and thermal sensation is essential to the develop-
ment of future burn pain pharmacology. Identification of polymodal
transient receptor potential (TRP) channels has been known to be the
most important finding in pain research in the last few decades [139,
140]. As part of this family, TRP vanilloid-1 (TRPV1) is a key channel ac-
tivated by heat, acidosis, chemicalmediators andmolecules such as cap-
saicin [141–145]. TRPV2 and TRP melastatin-3 have also been
demonstrated to play a role in thermal nociceptive sensation [146,147].
Research using TRPV1 knockout (KO) mice showed that TRPV1 is a
principle receptor responsible for thermal hyperalgesia during the
acute phase post burn injury (up to 24 h); while a recent study suggests
a role for TRPV1 in thermally induced chronic pain [144,148–151].
TRPV1 channels were also found to be involved in thermally induced
cell death [152], suggesting TRPV1 to be the target for both agonist
and antagonist pain control in burn injury. However, systemic delivery
may not be feasible as it has emerged that TRPV1 are implicit in homeo-
static roles [153,154]. Overcoming the barriers of systemic TRPV1 mod-
ulation remains unclear in burn pain management, therefore,
development and local application of TRPV1 modulators is expected to
avoid undesirable systemic and central effects.
Voltage gated sodium channels (Nav) have also garnered attention
as pharmacological targets for pain control.While a number of channels
have been identified in the literature, the three channel types which
show most promise in burn injury are Nav1.7, Nav1.8 and Nav1.9. Both
human studies and animal experiments have demonstrated the poten-
tial of Nav1.7 in burn patients demonstrating either complete absence of
pain response or conversely pathological states of pain [155–158]. Ani-
mal models demonstrated the potential utility of Nav1.7 to diminish
thermal andmechano-sensation in Nav1.7 knockoutmice – particularly,
in states of inflammation induced nociception [159,160]. A recent study
further confirmed that tetrodotoxin, a Nav1.7 blocker, significantly re-
duced thermal hyperalgesia andmechanical allodynia in a thermal inju-
ry model [161].
Innovation in pain management continues to improve acute and
long termoutcomes for patients experiencing the trauma of burn injury.
However, research surrounding burn pain analgesia can often suffer
from a lack of specificity. Future work to improve the current state of
managementmust not fall victim to a one-size-fits-all approach. The pa-
tient and burn characteristics, phase of injury, and category of burn pain
must all be considered to adequately address the needs of burn teams in
their clinical efforts. In consideration of this framework, the continued
development and understanding of mechanisms which contribute to
burn pain is an essential component for the development and improve-
ment of novel therapies.
5. Scarring and management
With reduced mortality rates associated with severe burn injuries,
the aim of burn wound care is shifting towards the management of
burn scars [162]. Hypertrophic and keloid scarring in burn patients
causes significant morbidity often with poor functional and cosmetic
outcomes (Fig. 2). Burn scars can lead to causes many debilitating fac-
tors including pain, pruritus, dyspigmentation, heat intolerance, and
limited range of motion due to scar contraction. The challenge in the
treatment of post burn injury scarring lays on finding new therapeutic
targets by an enhanced understanding of scar formation.
Fig. 2. 16-year-old patient with keloid scarring 6months following a 25% TBSA flame burn
injury. The wounds on his left upper arm and left chest were excised and grafted.
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5.1. Stem cells
Stem cell based wound healing therapies represents as a new prom-
ising modality for the treatment of fibrosis, scarring and treatment for
wound contraction. Post injury, stem cells are heavily involved in all o-
verlapped phases of wound healing [163–165]. Endogenous stem cells
migrate to the site of injury during the initial inflammatory phase,
where they elicit immunomodulation effects, followed by accelerated
wound closure, angiogenesis and re-epithelialization [166]. Mesenchy-
mal stem cells (MSCs) and adipose derived stem cells (ADSCs) have
been widely investigated in scar treatment, wound contraction and in
the pathophysiology of scar formation [167]. MSCs are defined as self-
renewing multipotent stem cells that can be differentiated into various
lineages of mesenchymal origin [163]. A number of studies have shown
the positive effects of bonemarrow-derivedMSCs in reducing hypertro-
phic scarring [168–170] via reduced expression of myofibroblast mark-
er and the down-regulation of collagen I synthesis. Recent studies have
further characterized two distinct phenotypes of MSCs involved in the
wound healing process: the pro-inflammatory M1 and the anti-inflam-
matory M2 [166]. This polarization is mediated by different toll-like re-
ceptors (TLRs), which respond to various substances in the extracellular
milieu and promote MSC phenotype switching accordingly to the cur-
rent needs of the organism. Specifically, stimulation of TLR3 and TLR4
switches the cell between an anti-inflammatory and pro-inflammatory
phenotype, respectively, resulting in control of cell migration, cytokine
secretion and ECM deposition. This research leads to a new direction
on the precise role of MSCs on wound healing and scar formation.
ADSCs have received considerable attention in skin regeneration as
it has potential to regenerate hypodermis, dermis and epidermis
[171]. An abundance of studies have supported the efficacy of fat
grafting in both aesthetic and reconstructive cases [172–174], which
has led to research into the utility of ADSCs in wound healing, regener-
ation of soft tissue, and reducing scarring [170,174,175] by its remodel-
ling capacity provided by the unique cytokine and growth factor
profiles. ADSCs treatment can diminish established hypertrophic scars
and keloids by the inhibition of transforming growth factor-beta 1
(TGF-β1) mediated fibroblast differentiation into myofibroblasts [164],
and reducing collagen deposition by up-regulating matrix metallopro-
teinases (MMPS), which are capable of remodeling collagen in the
wound site. In a recent study, burnwound exudatewas shown to signif-
icantly increase ADSC secretion of vascular endothelial growth factor
(VEGF) and interleukin-6 (IL-6), a pro-inflammatory cytokine [176].
ADSCs have also been found to promote vascularization and wound
healing through VEGF secretion and a decrease in TGF-β1 secretion in
a mouse model [168]. In line with these conflicting results, there is evi-
dence that ADSC stimulated cytokines promote granulation and angio-
genesis in the wound bed, which has been linked to the production of
hypertrophic scars in deep burns. However, few latest conflicting find-
ings demonstrated in addition to increased inflammatory responses,
ADSC stimulated cytokines promote granulation and angiogenesis in
the wound bed, which linked to the production of hypertrophic scars
in deeper burns [177–179]. Therefore, more research into the potential
role of ADSCs in burn scar treatment is required.
Innovations for the utility of stem cells in treating scars involve sur-
gical fat grafting with stem cells or introducing novel delivery methods
of stem cells into the wound site. A systematic review article showed
that fat grafting together with ADSCs enhanced wound angiogenesis,
decreased inflammation, improved burn scar size and quality in both
murine models and human studies [172]. Sundew-inspired adhesive
hydrogels combinedwith ADSCswas recently reported as an innovative
method to deliver ADSCs and was found to promote a “suturing” effect
to acceleratewound closure, although the effects on long term tissue re-
modeling or scar formation is not clear yet [180]. The effective delivery
of adipose-derived stromal cells using ECMpatch also holds promises to
reduce scarring. Stem cell delivery along with an ECM patch can im-
prove cell survival and proliferation, and significantly reduce fibrosis
[175]. Whether stem-cell-based therapies can be translated in clinical
practice is still in debate. Furthermore, practical barriers associated
with stem-cell-based therapies might restrict their utility in scarless
wound healing post burn injury [181]. To address this limitation, condi-
tioned media from umbilical cord-MSC cultures may be used to treat
wounds. Dermal fibroblasts were found to exhibit characteristics com-
parable to fetalfibroblasts, showing low capacity to formmyofibroblasts
[182]. Wounds treated with such umbilical cord-MSC-conditioned
media healed faster with decreased collagen accumulation. Additional-
ly, human amniotic-fluid-derivedMSC-conditionedmedia also have the
potential to inhibit the pro-fibrotic actions of TGF-β1 and even reverse
the myofibroblasts phenotype to a fibroblast-like state in vitro. Taken
together, innovations in stem cell studies provide more therapeutic op-
tions for treating burn scars.
5.2. Pharmacological approaches
5.2.1. Silicone
Silicone has been one of the gold standard for non-invasive burn scar
management of hypertrophic scars for years [183–185]. A recent ran-
domized clinical trial showed that theuse of silicone caused a significant
reduction in pain and pruritus at 6 months post-burn injury. The use of
pressure garments to reduce scar thickness, with silicone provided the
most optimal results [186]. Silicone gel sheets, however, are difficult
to use in anatomical areas subject to a high range of motion such as
joints and can be undesired in exposed areas such as the face. To over-
come these challenges, fluid silicone gel has been developed to allow
for a thin layer of silicone gel to dry into a transparent silicone sheet
[183–185]. Silicone is also being used to develop new devices such as
the Embrace, a dynamic stress shielding device showing good results,
however, evidence is still limited [187].
5.2.2. Corticosteroids
Injection of corticosteroids into hypertrophic scars has been consid-
ered a first-line of treatment for small hypertrophic scars scarring since
1960s. Corticosteroids are reported to reduce the height and volume of
scars, decrease pain and pruritus andmake scarsmore pliable [185,188].
Triamcinolone acetonide, a long acting corticosteroid, is commonly used
to treat post burn scarring. It is thought that corticosteroids decrease
collagen synthesis, attenuate cell proliferation of fibroblasts and
keratinocytes, and accelerate collagen degradation by activating colla-
genase and suppressing TGFβ [189–191]. However, the optimal dose
of corticosteroids for treatment have yet to be determined [185,188],
and the side effects of its use including hypopigmentation and subcuta-
neous atrophy [192] only represent a few limitations. A new approach
combining corticosteroids (Triamcinolone) and 5-fluorouracil (a pyrim-
idine analog antimetabolite chemotherapy agent) was shown to reduce
pain and have less side effects compared to the use of Triamcinolone
alone [193,194]. Furthermore, this combination in use with a pulsed-
dye laser has the potential to decrease scar volume and improve soften-
ing of hypertrophic scars and keloids [195].
5.2.3. Transforming growth factor-β modulators
TGF-β is a cytokine implicated in the pathogenesis of keloids and hy-
pertrophic scarring. It is produced and released by platelets, fibroblasts,
endothelial, epithelial and inflammatory cells and acts as a potent in-
ducer of myofibroblasts differentiation [196]. Previous studies have
confirmed that TGF-β1 and TGF-β2 promotes collagen synthesis and
scar formationwith significantly increasedmRNA expression in keloids.
In contrast, TGF-β3 is involved in scar prevention. Numerous research
and multiple therapies targeting the TGF-β pathway have been pro-
posed as advanced treatments for scars, aiming to reduce TGF-β activi-
ties, increase TGF-β3 expression, and utilize TGF-β inhibitors such as
decorin [197], proteolytic inhibitors such as mannose-6-phosphate
[198] and neutralized antibodies [199]. A recent study used antisense
oligonucleotides to block the effect of TGF-β1 over wound healing and
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tissue remodeling [196], and showed significantly reduced expression
of TGF-β1 and β2 with upregulation of TGF-β3 [200]. However, to
date, only the injection of TGF-β3 into surgical wounds have been
used to modulate the TGF-β pathway, demonstrating significant im-
provements in scar appearance in a randomized, controlled clinical
trial [201].
5.2.4. Botulinum toxin A
Botulinum toxin A is a neurotoxin produced by bacteria that inhibits
acetylcholine release from a neuron, and suppressesmuscle contraction
for approximate 2–6 months. Botulinum toxin has shown great poten-
tial as an additional tool to improve scar formation. Gassner and col-
leagues first reported that injection of botulinum toxin into the
underlying musculature of wound sites significantly enhanced wound
healing and minimized scar formation [202]. When botulinum toxin A
is injected into a wound, it causes flaccid paralysis of the surrounding
muscle, decreasingmechanical forces and thereby reducingwound ten-
sion [196,203]. Increased wound tension has been theorized to stimu-
late fibroblasts to differentiate into myofibroblasts and increase alpha-
smoothmuscle actin production, causing thewound to contract. There-
after, many studies were conducted by intralesional injection of botuli-
num toxin A to treat keloids or mature scar [204]. Clinical studies
followed up to 1 year showed that all patients that received botulinum
toxin A had excellent scar regression and flattening of the lesions. Al-
though the underlying mechanisms are still under investigation, re-
searchers suggest that botulinum toxin suppresses fibroblast
proliferation and differentiation by inhibiting the expression of TGF-
β1 [205]. In a recent study, reduction of the tensile force by botulinum
toxin A injection into themusculature adjacent to thewoundsmay rep-
resent a comprehensive mechanism of action for aesthetic improve-
ment of post-surgical scar [206]. All reported studies of botulinum
toxin A have focused on the improvement of scars however, whether
botulinum toxin A can prevent scar formation has yet to be established,
and more extensive research is required.
5.3. Surgical approaches
5.3.1. Fat grafting
Fat grafting as a surgical approach in treatment of burns has several
documented benefits and is a rapidly evolving field for scar modulation
[207–209]. Functional and aesthetic improvements were shown in
split-scar patients with reduced scar thickness and significantly better
results in pain, colour, thickness, pliability/movement and shape/relief
after 3 months [208]. A study on adherent burn scars showed a signifi-
cant improvement in elasticity and maximal extension, and of the pa-
tient observer scales score at the 3-month follow up [210]. In addition,
colour difference remained unaffected [210]. Fat grafting was also re-
ported to enhance wound closure and improve neuropathic pain
[211–215], and is further supported by a study that evaluated the effects
of fat-grafting on burn-induced neuropathic pain in rat-models [216,
217]. Moreover, several case series have demonstrated great improve-
ments in subjective patient ratings of burn scars, with improvements
in texture, softness, thickness, colour, and wound healing which were
also correlated histological findings [208,218–221]. ADSCs are believed
to play a key role in fat grafting as they reduced collagen deposition
and promoted vascularization and wound healing.
5.3.2. Laser therapy for scar modulation
Keloid and hypertrophic scarring occurs by the loss of control mech-
anisms involved in biosynthesis and tissue degradation during the
wound healing process, resulting in excessive collagen production and
fibroblast proliferation [222]. Although contraction is part of the regular
wound healing process [222], the contraction of healing burn wounds,
grafts and scar tissue results in abnormal scar formation [223,224]. In
addition, prolonged wound-healing and the inflammatory nature of
burn wounds lead to hypertrophic scarring [225], followed by pigment
alteration due to a dysbalanced amount of melanin or erythema [226,
227]. Laser treatment may serve as a useful modality for the treatment
of hypertrophic and keloid scars [228] that have shown very encourag-
ing results [207,229]. Over the last decade, laser therapy has become in-
creasingly popular and is increasingly a crucial part in reconstructive
burn surgery [224,230].
5.3.3. Pulsed dye lasers (PDL) & neodymium-doped yttrium-aluminium-
garnet (Nd:YAG) lasers
Wavelength-specific lasers, such as the PDL and Nd:YAG laser, that
selectively absorb oxyhaemoglobin and thus ablate blood vessels, have
been widely analysed for the treatment of hypertrophic burn scars
[151,207,231]. The mechanism of these vascular lasers still remains un-
clear, however, it has been postulated that selective photothermolysis
by targeted vascular destruction leads to tissue hypoxia, collagen fibre
heating, dissociation of disulfide bonds, catabolism and decreased cellu-
lar function, which consequently prevents excessive collagen deposi-
tion, and results in collagen fibre realignment and remodelling [223,
232]. The relative hypoxia of fetal skin leads to an upregulation of hyp-
oxia-inducible factor I, which subsequently upregulates oxygen-depen-
dent genes such as VEGF and TGF-β3, that results in a decrease in
fibroblast activity [233]. Histological analysis of scars treated with a
585-nm PDL revealed that thick hyalinised dermal collagen with hap-
hazardly arranged fibroblasts became looser, with less coarse collagen
fibres and a normal number of fibroblasts [234]. Ameta-analysis includ-
ing 28 well-designed clinical trials [232] showed that the 585/595-nm
PDL is effective in improving overall scar appearance and reducing
both scar height and degree of erythema of hypertrophic scars. It was
also found that to 585/595-nm PDL decrease scar pruritus [224,235],
andmay result in a synergistic actionwhen combinedwith intralesional
steroid or 5-fluorouracil injections [236].
5.3.4. Non-ablative and ablative fractional lasers
Novel techniques such as non-ablative and ablative fractional
resurfacing techniques are also developed to rehabilitate burn scars
[224,230,237]. Fractional lasers affect the scars only in small areas leav-
ing the surrounding skin uninjured, which serve as a reservoir of viable
tissue to stimulate neocollagenesis and tissue remodelling [229,237].
Non-ablative fractional lasers (NAFL) are particularly effective for the
treatment of atrophic, flat or mature scars [237]. A clinical trial demon-
strated that treatment of burn scars with NAFLs significantly improved
scar quality over a 6-month follow-up, and through histological analysis
collagen resembled normal skin [238]. However, it seems that treat-
ment of burn scars with an ablative fractional laser (AFL) triggers a
more vigorous reaction of neocollagenesis and tissue-rearrangement
when compared to NAFL [237,239].
Histological analysis demonstrates that the distinct AFL injury pro-
motes a cascade of heat shock proteins, matrix metalloproteinases,
and inflammatory processes, which result in a rapid wound healing re-
sponse with prolonged neocollagenesis and ensuing collagen remodel-
ling [240–243]. Tension of the scar is released and the dermal
architecture is rearranged by this remodelling process, leading to im-
proved pliability, decreased thickness, and better function [243–249].
Several groups reported a significant decrease in scar assessment scores
and a significant decrease in scar thickness when measured by ultra-
sound [230,240,242–244,250,251]. Recent reports demonstrate that
even one treatment with the AFL can lead to significant improvements
in scar quality (Fig. 3) and symptoms (such as pruritus and neuropathic
pain), heat-sensitivity, and a measured decrease in scar thickness, irre-
spective of the scar maturation status [230,244].
Laser-facilitated drug delivery combined with fractional resurfacing
is another advanced technique to further enhance pliability and reduce
thickness [252,253]. This combination canhelp to reduce adverse effects
from the local accumulation of intralesional injected steroids or 5-fluo-
rouracil by assisting the evendistribution of the drug in the dermis [252,
254–256]. Laser treatment represents a therapy that has the potential to
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fill the gap between non-surgical treatment options and surgical inter-
ventions for scar management [237]. It can also be used before surgery
to make scars more pliable, to potentially improve surgical outcomes
[230] or in scar rehabilitation to limit the development of contractures,
promoting early mobility and thus accelerating the entire rehabilitative
process [237,249]. However, the exact mechanisms by which lasers can
achieve beneficial scar modulation remain unclear. Most data
supporting its clinical application stem from retrospective series, thus
being prone to selection bias and similar. Therefore, more prospective
studies using in depth molecular analyses to explain treatment effects
and patient outcomes are required to determine the exact role for this
novel, promising therapeutic strategy for burn scars.
6. Skin tissue engineering in treatment of burn injury
Skin tissue engineering provides a new tool in treatment of burn in-
jury, aiming to enhance wound healing, trigger skin regeneration and
reduce the long term consequences of scarring [257]. The ultimate
goal of skin tissue engineering is to produce a ‘living skin’ which offers
completely functional skin, including all skin appendages to replaces
human skin in its entirety. Challenges and problems in skin tissue engi-
neering include poor vascularization; delayed cell infiltration and mi-
gration due to undesirable surface structure or lack of cell-recognition
signals or poor mechanical strengths. Researchers therefore pay their
attentions into developing innovative biomaterials, advanced formula-
tion technologies or new methods to incorporate autologous cells (e.g.
keratinocytes, dermal fibroblasts, melanocytes) in order to increase
the complexity of the skin substitutes. The applications of skin tissue en-
gineering are broad, ranging from basic scaffolds to aid the growth of
the neodermis, to the delivery of biomolecules such as growth factors,
and stem cells to enhance wound healing and skin regeneration with
full functional skin.
6.1. Biomaterials in skin tissue engineering
Both natural polymers and synthetic polymers have been widely in-
vestigated in skin tissue engineering. Natural polymers are isolated
from a variety of sources including animal (collagen, hyaluronic acid),
seaweed (agarose, alginate) or bacteria. They are soluble in aqueous
or buffer solutions and are biodegradable in vivo. Collagen and
hyaluronic acid (HA) are two major components for skin regeneration
and have been fabricated as sponges, films, matrices and gels to
facilitate wound healing utilising the biodegradability and biocompati-
bility properties that make these polymers favourable [258–262]. Colla-
gen scaffolds promote the strong attachment and proliferation of
keratinocytes and dermal fibroblasts with various collagen based skin
templates such as Biobrane™, MatriDerm®, Apligraf® and Integra®
currently used in burn injurywound care. Hyaluronic acid (HA) is a nat-
ural polysaccharide composed of N-acetylglucosamine and glucoronic
acid sugar units. HA is a structural component of skin ECM and due to
its low immunogenicity, it has been considered as an ideal biomaterial
for wound repair [260–262]. However, poor physical properties of HA
represent serious limitations for its medical application. Chemical mod-
ification with enhanced resistance to degradation has significantly im-
proved physical properties of HA, resulting in two commercial
products: Hyalomatrix and Hyalosafe that are currently used in burn
treatment as dermal substitutes.
6.1.1. Elastin
Elastin is an essential component of native human skin, providing
structural and cell mediating functions [263]. Recent studies demon-
strated that incorporation of elastin in skin substitutes can improve
scar quality and enhances angiogenesis [264,265]. In a clinical study,
collagen-elastin scaffolds were found to reduce wound contraction
and improve scar tissue architecture [265]. Reducedwound contraction
was attributed to a decrease in the number of fibroblast differentiating
into myofibroblasts [263,266]. The ability of elastin to enhance angio-
genesis has led to the introduction of one-step procedures in burn sur-
gery. Currently, many dermal skin substitutes involve two-step
procedures as skin substitutes need time to be fully integrated with
the wound bed and vascularized, prior to a secondary surgical step of
split-thickness skin grafting. Otherwise, skin grafting will fail and result
in skin graft loss and poor take. MatriDerm® is the first commercialized
skin substitute containing elastin. MatriDerm® has been proven to be
applicable in one-step procedures without a reduction in skin graft
taken rate [267–271] and it was also found effective in a range of
acute and reconstructive burn wounds.
6.1.2. Silk
Silk is composed of two proteins, fibroin and sericin. The favourable
characteristics of silkmake it as an optimal biomaterial in skin tissue en-
gineering to enhance biocompatibility, mechanical structure with con-
trollable biodegradability [272,273]. Silk are widely investigated in
tissue engineering studies, including hard tissue, e.g. bone/cartilage
and soft tissue, e.g. eye and neuron regeneration. In skin tissue engi-
neering, silk was found to promote collagen synthesis from dermal fi-
broblasts [274] and 3D silk scaffolds are being optimized as a new
generation of skin substitutes. A recent study showed that scaffold in-
corporation of silk and hair-derived keratin as a dermal substitute, re-
sulted in better cell adhesion and proliferation of fibroblasts, and
increased collagen protein expression [275]. The advantages of using
silk in skin tissue engineering are further expanded in combination
with keratin, collagen, elastin, chitosan, fibronectin and synthetic mate-
rials [272–274].
6.2. Advanced technologies in skin tissue engineering
6.2.1. Recombinant proteins
In addition to advancements in biomaterials, artificial ECM proteins
are being produced to diminish the risk of disease transmission and to
reduce host immunological responses, yet maintain a high bioactivity
for wound healing [17]. Typically using E. coli or yeast systems, recom-
binant proteinswith designed structures and functions can be produced
by genetic manipulation. A variety of recombinant proteins are current-
ly being investigated, such as tropoelastin, a precursor to elastin. Our
research team recently investigated the effects of tropoelastin incorpo-
rated into Integra®, and found that tropoelastin has a comparable
Fig. 3. (A) A 19 year old patient with hypertrophic scarring on his left ankle 7 months
following a burn injury with hot oil. The scar was unstable and led to frequent wound
breakdown depending on the footwear. (B) 6 weeks following one treatment with
the ablative fractional Ultrapulse® CO2 laser and laser facilitated steroid infiltration, the
scar has flattened, became more pliable, pain and itchiness improved, and wound
breakdown subsided.
9Y. Wang et al. / Advanced Drug Delivery Reviews xxx (2017) xxx–xxx
Please cite this article as: Y. Wang, et al., Burn injury: Challenges and advances in burn wound healing, infection, pain and scarring, Adv. Drug
Deliv. Rev. (2017), https://doi.org/10.1016/j.addr.2017.09.018
function to bovine derived elastin [264]. Tropoelastin incorporated
Integra® significantly increased angiogenesis in both mouse and por-
cine wound repair models compared to skin grafting only [264]. In con-
trast, injection of tropoelastin into a porcine hypertrophic burn scar
showed no changes in scar flexibility [276]. Research into recombinant
collagen is also under taking, but the complex structure of collagen
makes it more challenging in tissue engineering. The production of
recombinant collagen is limited by the lack of an animal-cell-specific,
post- translational enzyme system. Although the gram-positive bacteri-
um, Streptococcus pyogenes, has been found to produce a stable and
thermal resistant collagen, it lacks specific binding sites native to
human collagen [277,278]. This represents the framework for recombi-
nant collagen engineering and further studies aim to improve its com-
plexity in comparing to native human collagen. Recombinant proteins
as building blocks for skin substitution is progressing, limitations in-
cluding the lack of production in commercially required quantities and
insufficient knowledge regarding protein structure-function relation-
ships needs to be overcome [278].
6.2.2. Electrospinning
Electrospinning was developed over 30 years ago but has attracted
new interest in the last decade [279]. Using this technique, nano-scale
fibers can be produced tomimic ECM in native human skin. Amajor ad-
vantage of electrospinning technology is the ability to spin both natural
polymer such as silk, chitosan, gelatin, fibrinogen and synthetic mate-
rials such as Poly (ε-caprolactone (PCL), polyurethane (PU), poly
(glycolic acid) (PGA) and poly (L-lactide) PLLA [280–282] or copolymer
together. Research attempts to combine various natural and synthetic
materials to enhance the biocompatibility as well as the mechanical
strength of scaffolds [282]. In order to overcome poor infiltration of
cells into electrospun scaffolds due to low porosity and small pore
size, many advancedmethods have been developed, including leaching
of selective water-soluble fibers [283] and cell-nanofiber fabrication. A
successful approach involved repeatedly seeding fibroblasts layer-by-
layer into electrospun scaffolds until the desired number of cell-nanofi-
ber layers were achieved [284]. Adoption of coaxial electrospinning sys-
temhas also shown excellent results in cell infiltration and proliferation
[285]. Additionally, theunique properties of coaxial electrospinning sys-
tem has been utilised in drug and bioactive molecule delivery as it can
protect the bioactivity of bioactive molecules by spinning two separate
layers of nanoscale fibers that contain both polymer solution and bioac-
tive molecules [281].
6.2.3. Three-dimensional (3D) bioprinting
3D bioprinting is an advanced manufacturing platform that enables
the predefined deposition of living cells, biomaterials and growth fac-
tors using computer-aided design (CAD) technology. Bioprinting tech-
nology has the potential to directly create graded macroscale
architectures to better mimic the natural ECM, thereby augmenting
cell attachment and proliferation [286]. Bioprinting is also to produce
microfeatures, such as ridges and modulated surfaces by usingmultiple
material platforms with various dispensing mechanisms [287]. There
are three important steps in 3D bioprinting, including pre-processing
(3D model generation and bio-ink preparation); 3D bioprinting and
post-processing (using a bioreactor for tissue regeneration). 3D
bioprinting of skin is receiving great attention as it can rapidly produce
an even landscape by allowing an increasingly controlled and precise
deposition of cells into a predefined tissue structure. Various biomate-
rials have been evaluated for bioprinting skin such as collagen [288], bo-
vine gelatin [289], chitosan and silk fibrin [290], also synthetic
biopolymers being PCL, poly (lactic acid) PLA, poly (lactide-co-
glycolide) PLGA and PLLA [291] or human plasma [292]. Additionally,
keratinocytes and fibroblasts are two widely studied cell types in 3D
bioprinting skin [289]. A recent study successfully demonstrated the de-
position of 20 layers offibroblasts and 20 layers of keratinocytes, respec-
tively, in collagen using laser-based bioprinting. The results showed the
presence of cadherin and connexin 43 in the epidermis, which are fun-
damental for tissue morphogenesis and cohesion [293]. Furthermore, a
3D bioprinted skin using keratinocytes and fibroblasts in collagen
showed good graft take, and blood vessel formation/growth in the sur-
rounding wound area in nude mice at 11 days post transplantation
[294]. In order to regenerate fully functional skin, co-bioprinting mela-
nocyteswith keratinocyte; or incorporating endothelial cells to facilitate
angiogenesis should be evaluated in future studies [291]. The integra-
tion of pilosebaceous units, with hair follicles and sebaceous glands in
skin substitutes remains an unsolved challenge.
Skin tissue engineering has evolved from two dimensional supports
to multifunctional complex systems, providing platforms for support,
drug delivery, and the foundation for tissue regeneration. Limitations
in current available products have led to developments in the use and
applications of new materials and techniques. These advancements
aim to optimize skin substitutes and ultimately improve patient quality
of life.
7. Conclusion
Significant advancements have been made in burn injury manage-
ment and research in the past decade, including developments in
novel skin substitutes; application of new antimicrobial wound dress-
ings and enhanced systemic drug delivery for wound infection; testing
new pharmacological interventions and finding new targets for
wound pain control; together with advanced surgical approaches such
as laser therapy, fat grafting, skin grafting and coverage options. As a re-
sult, the survival rate of severe burn injury patients has been improved
with significantly reduced hospital stay, resulting in decreased costs to
patients and medical providers. However, several challenges still need
to be solved to continue to improve current burn care. In particular, in-
vestigating how to accelerate wound healing, attenuate burn induced
hypermetabolic-catabolic conditions, control systemic infection and re-
duce the overall time for functional recovery, should be prioritized. Fur-
ther research will continue to optimize current treatment paradigms
and identify novel targets in burn care to ultimately enhance the out-
come for severe burn injury patients.
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Abstract  
Background 
Dermal regeneration is critical for quality wound healing in treating deep burns. 
MatriDerm, a non-cross-linked collagen-elastin dermal template, is commonly used 
in full-thickness wound repair, to promote dermal regeneration and improve scar 
tissue quality. Due to the non-cross-linked status, its porous protein structures are 
mechanically weak and go through quick biodegradation once grafted. Cross-linking 
the collagen-elastin template could potentially enhance its stability, strength and 
performance as a dermal scaffold. 
  
Aim 
The aim of this study was to investigate the effects of cross-linking on MatriDerm 
stability, cell interaction, biodegradation and wound contraction using established cell 
culture and murine models.  
  
Method 
MatriDerm was cross-linked with glutaraldehyde vapour (2.5%) and characterized in 
comparison with non-cross-linked MatriDerm. Scaffold properties including surface 
morphology, in-vitro stability and strength were assessed through scanning electron 
microscopy, measurement of protein loss with an assay kit, and tensile modulus 
testing, respectively. Cell-scaffold interaction, cell proliferation and migration were 
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examined using cultured human dermal fibroblasts. The scaffold biodegradation and 
its impact on wound healing and contraction were studied in a murine model.  
  
Results 
Cross-linked MatriDerm displayed a slight but significant reduction in average pore 
size, a significant reduction of total protein loss and a 3-fold increase in tensile 
strength compared to the non-cross-linked template. In-vitro studies observed a 
significant increase of fibroblast proliferation and migration in cross-linked MatriDerm 
and reduced scaffold contraction compared to non-cross-linked MatriDerm. In the 
murine model, non-cross-linked MatriDerm was almost completely biodegraded at 
day 14 after grafting but cross-linked MatriDerm remained intact. Interestingly, in-
vivo study showed no significant difference in wound contraction between cross-
linked and non-cross-linked MatriDerm. Similar host response was observed in both 
scaffold groups.  
  
Conclusion  
Cross-linked MatriDerm showed a significant increase in stability and strength 
compared to non-cross-linked MatriDerm, enhancing its durability and cell-scaffold 
interaction. In the murine model, cross-linked MatriDerm showed a reduced 
biodegradation rate and a similar host response but a comparable wound 
contraction. The extended exposure of cross-linked MatriDerm in a wound could 
potentially have beneficial effects on scar tissue, promoting the formation of a more 
pliable, healthy scar.  
 
1. Introduction 
Full-thickness skin defects from burns or trauma are traditionally treated by skin 
grafting, in the majority of cases with an autologous split thickness skin graft, as one 
of the primary steps of the reconstructive ladder. These autologous split thickness 
skin grafts are harvested from the patient at the junction of the papillary dermis and 
thereby only include a very small amount of dermal elements. Split thickness skin 
grafts generally cover a well-vascularised wound bed effectively but due to the lack 
of a fully intact dermis significant scarring is a common outcome. Associated not only 
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with aesthetic issues, in specific anatomical areas significant scarring can cause 
contractures, causing severe functional disabilities.[1, 2] In many burn victims, 
scarring issues become an enduring life-long debilitating consequence of their 
injuries.[3] 
In 1980, when the first artificial collagen dermal template chemically cross-linked with 
glutaraldehyde was introduced [4-7], the reconstructive ladder changed, introducing 
dermal regeneration by bioengineered soft tissue reconstruction. Throughout the 
following decades, dermal substitutes have been developed to replace the damaged 
dermis and to provide scaffolding structures for cell attachment, ingrowth and 
angiogenesis to generate a neodermis. Dermal substitutes are now available as a 
variety of porous structures with components including matrix proteins and synthetic 
polymers.[8-11] Cross-linking treatment of protein-based dermal scaffolds is one of 
many procedures to stabilize the proteins so that the scaffolding structure can be 
maintained for sufficient time to allow for cell infiltration and tissue regeneration, 
increasing its durability in-vivo.[12] MatriDerm, a bovine collagen-elastin matrix, is 
one of the commercial available dermal substitutes for dermal regeneration. 
MatriDerm is a non-cross-linked porous scaffold and proven to be an effective 
dermal substitute.[13-15] It is the only dermal template that is available that has 
elastin incorporated into the scaffold. As the human native dermal extracellular 
matrix is composed of 2-4% elastin (dry weight), providing an essential structural and 
mechanical role [16], the addition of elastin in similar proportions in a dermal 
regenerative template allows the template to resemble the natural extracellular 
matrix more closely.  
However, due to the non-cross-linked form of MatriDerm, the scaffold is expected to 
biodegrade relatively quickly in-vivo. In a study comparing five commercially 
available dermal substitutes in a porcine model, MatriDerm was noted to biodegrade 
faster compared to Integra, fragmenting and losing its structure by day 21 whilst 
Integra was still fully intact.[17] If the scaffold structures are too weak in mechanical 
strength the scaffold will biodegrade quicker and affect the full regeneration of skin 
tissue. Fast degradation rates has been shown to influence host response and 
thereby potentially leading to poor quality scar tissue [18], affecting the formation of 
contractures and aesthetic outcome. By possibly decreasing the rate of 
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biodegradation over time, the extended presence of a more natural supporting 
scaffold could enhance dermal regeneration. Further research is required to optimize 
the structure of dermal substitutes to improve their efficacy in both scar tissue 
formation and its application in skin tissue engineering. This study is designed to 
investigate if the in-vitro and in-vivo performance of MatriDerm as a bioscaffold could 
be further improved by cross-linking to enhance its biostability and extend cell-
scaffold interaction for neodermal development. 
 
2. Materials and Method 
(For a full list of materials/reagents, please see page 45-46) 
2.1 MatriDerm 
MatriDerm (MedSkin Solutions Dr. Suwelack AG, Germany) is an acellular dermal 
regeneration substitute made of native bovine collagen type I, III and V and 3% 
alpha-elastin hydrolysate from bovine nuchal ligament. It is sterilized through 
gamma-radiation and can be stored at room temperature. It is available in various 
sizes with a thickness of either 1 mm or 2 mm. For all in vitro and in vivo analysis in 
this study, 1 mm-thick MatriDerm samples with a surface area of either 1 cm2 or 0.5 
cm2 were prepared using a scalpel blade or an 8 mm biopsy punch, respectively.     
 
2.2 Cross-linking MatriDerm 
MatriDerm samples were cross-linked by glutaraldehyde 2.5% (v/v) vapor treatment 
in a glass desiccator over a period of 24 hours at room temperature (humidity of < 
60%). The cross-linking process was ceased by treating the samples with 0.2M 
glycine in reverse osmosis water. The samples were then sterilized using 80% 
ethanol (v/v) for 3 hours and washed 6 times in sterile phosphate buffered saline 
(PBS) to remove residual glutaraldehyde. In order to dry the scaffolds, samples were 
removed from the PBS wash and placed on filter paper to soak up any residual PBS. 
All cross-linked and non-cross-linked samples were stored dry and sterile at 4˚C 
prior to further assessments. 
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2.3 Characterization of cross-linked and non-cross-linked MatriDerm 
2.3.1 Uniaxial tensile tests 
Uniaxial elongation tensile tests were performed in an unconfined state using an 
Instron (Model 5543) with a 10 N biological load cell, according to previously 
described testing procedures.[19-21] Samples were soaked in PBS for 2 hours at 37 
°C prior to mechanical testing (n=3 for each group). Samples measured at a height, 
thickness and width of 26.87 ± 3.55 mm, 0.99 ± 0.10 mm, 9.84 ± 0.67 mm, 
respectively. For the uniaxial tensile tests, the samples were subjected to a loading 
and unloading cycle at 37 °C, the load (N) was applied at a cross speed of 0.05 
mm/min. The Young’s modulus was obtained from the slope of the stress– strain 
curve generated over the linear portion of the strain range after the initial toe region. 
A determination of the ultimate tensile strength was not practical due to the designed, 
inherent friability of the constructs, which included failure at the grips.  
 
2.3.2 Stability  
0.5 cm2 samples of cross-linked or non-cross-linked MatriDerm were placed in 500 
µL of PBS each and placed on a shaker for gentle circulation (60 rpm) of PBS 
around the samples in a consistent environment of 37°C over 35 days (n=3 for each 
group). PBS was collected every two days and replaced with fresh PBS. The protein 
concentration in PBS was determined by bicinchoninic acid assay and compared 
with a calibration curve constructed using a series dilution of bovine serum albumin 
in PBS. The released protein was subsequently calculated as % w/w and used to 
assess the influence of cross-linking on protein biodegradation.  
 
2.3.3 Surface morphology 
Surface morphology of non-cross-linked or crosslinked MatriDerm was examined 
using a scanning electron microscope (SEM) (JEOL JSM-6380, JEOL Ltd., Tokyo, 
Japan) (n=2 for each group). Dry, sterile specimens were mounted on aluminum 
sample stubs and sputter-coated with platinum using an auto coater (JFC-1600 Auto 
Fine Coater, JEOL Ltd., Tokyo, Japan) prior to examination in the SEM at a voltage 
of 15 kV.  
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2.3.4 Quantification of pore size and porosity 
Pore size was determined by measuring 30 randomised pores on SEM images of 
cross-linked and non-cross-linked MatriDerm using a java-based image processing 
program (Image J, Laboratory for Optical and Computational Instrumentation, United 
States of America) (n=3 for each group). Pore size was measured by two 
independent observers. To determine porosity, samples of cross-linked and non-
cross-linked were fixed in 10% formalin for 24 hours prior to tissue processing and 
embedded in paraffin blocks (n=3 for each group). Sections of 5 µm were stained 
using haemotoxylin and eosin (H&E). Stained sections of non-crosslinked and cross-
linked MatriDerm were imaged using a microscope cell imaging system (EVOS 
M7000 Cell Imaging System, ThemoFisher Scientific, United States of America) at a 
magnification of x20 and black and white binary conversion was generated using 
Image J. The porosity was calculated using images J and defined as percentage of 
inter-fibre space relative to the total scaffold area measured. 
 
2.4 In-vitro analysis: Human dermal fibroblast interaction with cross-linked and non-
cross-linked MatriDerm 
2.4.1 Cell proliferation and distribution 
Primary human dermal fibroblasts (passage 4) provided by the Concord Repatriation 
General Hospital Burns Research Lab were harvested and seeded onto either cross-
linked and non-cross-linked MatriDerm samples at a density of 100,000 cells/cm2 
(n=3 for each group, for each time point).  Human dermal fibroblasts seeded 
scaffolds were cultured in Dulbecco Modified Eagle Medium (DMEM) supplemented 
with 10% (v/v) fetal bovine serum, 2 mM L-glutamine and 100 U penicillin-0.1 mg 
streptomycin-0.2 mg neomycin/mL. Cell seeded scaffold were incubated at 37°C and 
5% CO2 under steady state condition and were collected on day 1 and 14 post-
seeding. All cell seeded scaffolds were fixed in 10% (v/v) neutrally buffered formalin 
for 24 hours and subsequently dehydrated for 24 hours in 70% (v/v) ethanol. Further 
dehydration was performed with 100% ethanol and multiple incubations with xylene. 
After x3 soaks of paraffin, the cell seeded scaffolds were embedded in paraffin 
blocks and sectioned at a thickness of 5 µm. Sections were collected every 200 µm 
aiming to quantify cell population throughout each cross-section and determine cell 
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distribution evenly throughout the entire sample. Samples were then stained with 
Masson’s Trichrome staining and cell numbers were counted manually using a light 
microscope at days 1 and 14 by two independent researchers in each collected 
section. Cell proliferation and cell distribution throughout the samples was compared 
between cross-linked and non-cross-linked MatriDerm.  
 
2.4.2 Scanning electron microscopy of human dermal fibroblast seeded scaffolds 
Cell morphology of human dermal fibroblasts seeded on cross-linked and non-cross-
linked MatriDerm was examined using a SEM. Cell seeded scaffolds were removed 
from the culture plates at day 1 and 14 post cell seeding (n=3 for each group, for 
each time point). After rinsing three times with PBS, cell-seeded templates were 
primarily fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer for 2 
hours. Samples were rinsed with cacodylate buffer before the secondary fixation with 
using 2% osmium tetroxide. The fixed cell seeded scaffolds were washed with 
sodium cacodylate buffer and dehydrated in a series of x5 successively higher 
ethanol dilutions starting at 50% (v/v) and completing the process with 100% 
molecular sieved ethanol. Samples were rinsed twice-thrice for 2 minutes in each 
solution. The specimens were air-dried, mounted on aluminum sample stubs and 
sputter-coated with platinum prior to examination in the SEM at a voltage of 15 kV. 
 
2.4.3 Contraction of human dermal fibroblast seeded and non-seeded scaffolds 
Prior to proliferation and morphology analysis, cell seeded scaffolds were measured 
in their respective culture plates to monitor in-vitro contraction of the scaffolds at day 
1 and 14 post-seeding (n=4 for each group, for each time point). Images were taken 
of the scaffolds in their respective culture plates and the diameter of each template 
was measured using Image J in reference to the diameter of the culture well. 
Measurements were performed by two independent researchers. 
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2.5 In-vivo analysis of cross-linked and non-cross-linked MatriDerm in a murine 
model 
2.5.1 Murine model 
Pathogen-free, male Balb/c mice, aged 12 weeks and weighing in average of 
23.5±0.7 g were used for this study (n=3 for each group, for each time point). All 
animals were housed in standard approved cages with free access to water, in the 
Molecular Physiology Unit of the ANZAC Research Institute. The environment was 
closely controlled at 24-26°C and 44-46% humidity under a 12:12hr light dark cycle 
with lights on at 6am. All protocols for this study were approved by the Sydney Local 
Health District Welfare Committee (Protocol No. 2013/019) under the National Health 
and Medical Research Council guidelines for animal experimentation. A two-wound 
model was used for this study. Each mouse was anesthetized individually via intra-
peritoneal injection of a mixture of ketamine (50 mg/mL) and xylazine (50 mg/mL) at 
0.01 mL/g of body weight. On each mouse, dorsal area was shaved and two 
adjacent but identical full-thickness skin excisions of 1 cm2 were created surgically. 
The wounds were covered with either non-crosslinked or cross-linked MatriDerm 
templates followed by full-thickness skin grafts from the opposite site superimposed 
onto the template, creating an autograft. Both grafts were sutured in place with 5-0 
silk, dressed with Atruaman, IV 3000 and an elasticated circular dressing to protect 
the dressing and skin graft. Carprofen (5 mg/kg) was given at the time of 
anaesthesia and then on the following two days post-operatively for analgesia. After 
surgery, each mouse was caged individually for the first 3 days and then two mice 
per cage thereafter with free access to water and food. Skin graft take was 
macroscopically observed and contraction was quantified by measuring wound size 
with VISITRACKTM Digital Portable Device on days 0, 3, 5, 7, 10, 14, 21 and 28 
using a wound grid. Wound size was then measured using VisiTrack digital system 
by two independent researchers. 
 
2.5.2 Histology  
Skin biopsies from the murine model were collected on day 7, 14, and 28. Biopsies 
were fixed in 10% (v/v) formalin, embedded in paraffin and sectioned at 5µm 
thickness. Cross-sections were deparaffinised in xylene and dehydrated in a series 
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100% ethanol. To stain nucleic material purple, samples were incubated in Harris’ 
Haematoxylin for 5 minutes and then washed with tap water and acid alcohol (0.3% 
(v/v) HCl in 70% (v/v) ethanol). Pink staining of the remaining tissue was achieved by 
30 second incubation in alcoholic eosin. Following a wash in tap water and another 
series of dehydration in 100% ethanol and xylene, samples were examined under a 
brightlight microscope (Olympus BX60, Olympus, PA, USA). Microscopic skin graft 
take (viability of graft), scaffold degradation, cell infiltration and vessel formation 
were assessed by two independent researchers. Images of the samples were taken 
using a microscope cell imaging system (EVOS M7000 Cell Imaging System, 
ThemoFisher Scientific, United States of America).   
 
2.6 Statistics 
Data is expressed as mean ±  standard deviation. Significance was evaluated with a 
F-test and two sample T-test were performed for two groups, p value of <0.05 was 
defined as statistically significant. ANOVA was used in groups greater than two.  
 
3. Results 
3.1 Characterization of cross-linked and non-cross-linked MatriDerm 
3.1.1 Uniaxial tensile test results 
Cross-linked MatriDerm was noted to be a macroscopically firmer, spongy scaffold 
when moistened compared to its more fragile non-cross-linked counterpart. The 
tensile modulus of the constructs, non-crosslinked and crosslinked, was obtained 
from the slope of the stress-strain curve generated over the linear portion of the 
strain range after the initial toe region. The result from this mechanical analysis of 
the scaffolds showed that the crosslinking of the constructs resulted in a significant 
increase of tensile modulus by 3-fold. A minor effect on energy loss was noted in 
cross-linked MatriDerm, when the strain level reached above 15%, however, no 
cracks or torsions were observed in the samples. Tensile modulus displayed an 
average of 268.8 ± 27.9 kPa for cross-linked MatriDerm compared to 98.1± 12.6 kPa 
for non-cross-linked MatriDerm (Fig.1a). 
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3.1.2 Scaffold stability results 
Scaffold stability testing was conducted based on protein release from the scaffolds 
into PBS at 37oC. The results showed a significant higher release rate of protein 
from non-cross-linked MatriDerm compared to cross-linked MatriDerm over a period 
of 35 days (Fig. 1b). Initially, a burst release was observed on day 1 for both non-
crosslinked and cross-linked scaffolds. However, non-cross-linked MatriDerm 
released approximately 165.1 ± 11.2 µg of protein on day 1 which is significantly 
higher than the cross-linked MatriDerm that only released  33.8 ± 2.4 µg on the 
same day. Subsequently, both scaffolds developed a plateau release of protein. 
Non-cross-linked MatriDerm reached a plateau on day 11, earlier than cross-linked 
MatriDerm. On day 17, when both scaffolds had reached their plateau. Non-cross-
linked MatriDerm released protein at a rate of 9-11 µg per day and cross-linked 
MatriDerm released protein at a rate of 2-3 µg per day. In total, the protein released 
from non-cross-linked MatriDerm was 407.3 µg after 35 days and 107.4 µg for cross-
linked MatriDerm. This result indicated that after crosslinking, MatriDerm is more 
advanced in preserving protein release and is expected to degrade at a reduced 
rate. 
 
3.1.3 Pore size, porosity and morphology results 
Cross-linked MatriDerm displayed a slight but significant decrease in pore size and 
porosity compared to non-cross-linked MatriDerm. Pore size was visibly reduced 
under electron microscopy, forming condense and compressed fibres with a thicker 
width compared to those of non-cross-linked MatriDerm (Fig. 2a). Pore size was 
found to be reduced by approximately 1.5 µm in cross-linked MatriDerm compared to 
non-crosslinked MatriDerm. Average pore size of non-cross-linked MatriDerm was 
measured at 26.5 ± 4.0 µm and of cross-linked MatriDerm at 25.0 ± 4.8 µm (Fig. 2b). 
Porosity was significantly decreased in cross-linked MatriDerm, resulting in 13.94% 
reduction of porosity in cross-linked compared to non-cross-linked MatriDerm (Fig. 
2c). Furthermore, from cross-sectioning samples of cross-linked MatriDerm, less 
pores and visibly thickened, structured fibres of collagen and elastin were noted, 
creating a compacter form of MatriDerm (Fig. 2d).  
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3.2 In-vitro analysis results: Human dermal fibroblast interaction with cross-linked 
and non-cross-linked MatriDerm 
3.2.1 Scaffold contraction 
At the initial stages of seeding cross-linked and non-cross-linked MatriDerm with 
human dermal fibroblasts, macroscopic contraction was observed in cell culture 
conditions over 14 days. (Fig. 3a). Non-cross-linked MatriDerm decreased by 2.12 ± 
0.13 mm in diameter and cross-linked MatriDerm displayed a mild contraction of 1.19 
± 0.30 mm on day 1 (Fig. 3b). Non-cross-linked MatriDerm reduced another 0.93 mm 
in diameter further and by day 14 had reduced to a size of 4.95 ± 0.15 mm in 
diameter; a 38% contraction compared to its original size. In contrast, cross-linked 
MatriDerm displayed minimal contraction, reducing another 0.15 mm in 14 days, 
resulting in a diameter of 6.66 ± 0.38 mm at day 14; 17% contraction compared to its 
original size. Cross-linked MatriDerm was measured significantly larger (1.71 mm 
more in diameter on day 14) compared to non-cross-linked MatriDerm.  
Comparison of scaffold diameter was also made between non-cross-linked 
MatriDerm samples with and without cell seeding, and cross-linked MatriDerm 
samples with and without cell seeding to determine whether scaffold contraction was 
attributed to the human fibroblasts or the scaffold itself. No significant difference was 
found in size between cell-seeded and non-cell-seeded scaffolds. Non-cross-linked 
MatriDerm showed diameters of 4.95 ± 0.15 mm with cells and 4.91 ± 0.30 mm 
without cells whilst cross-linked MatriDerm showed diameters of 6.66 ± 0.38 mm with 
cells and 6.63 ± 0.21 mm without cells by day 14 (Fig. 3c and d).  
 
3.2.2 Cell proliferation   
Dermal fibroblast interaction with cross-linked and non-cross-linked MatriDerm 
showed a significant increase in cell quantity of cross-linked MatriDerm compared to 
non-cross-linked MatriDerm (Fig. 4a). On day 1, cell quantity was found similar 
between cross-linked (50,745.7 ± 5,383 fibroblasts) and non-cross-linked MatriDerm 
(52,179.3 ± 4,706 fibroblasts). After 14 days, dermal fibroblasts proliferating on 
cross-linked MatriDerm duplicated in number (102,802.3 ± 15,797 fibroblasts), 
displaying a significant growth of 103% compared to day 1. Dermal fibroblasts 
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seeded onto non-cross-linked MatriDerm only showed growth of 17% in 14 days 
(60927.0 ± 4005 fibroblasts). 
 
3.2.3 Cell migration and distribution 
Dermal fibroblasts tended to migrate throughout cross-linked MatriDerm from day 1, 
more evenly distributed compared to non-cross-linked MatriDerm, with cell growth 
extending towards the periphery. On day 1 it was found that dermal fibroblasts 
seeded on cross-linked MatriDerm commenced cell migration immediately from the 
centrum dispersing throughout the scaffold, whereas dermal fibroblasts seeded onto 
non-cross-linked MatriDerm were mainly concentrated in the centre (Fig.4b). On day 
14, majority of the dermal fibroblasts seeded on non-cross-linked MatriDerm were 
still located in the central area of the scaffold, whereas cross-linked MatriDerm 
demonstrated more cell migration and proliferation to the outermost edges of the 
scaffold (Fig. 4c).        
Dermal fibroblast migration and distribution was visualised under SEM showing 
centrally confluent cells in both non-cross-linked and cross-linked MatriDerm on day 
1 (Fig. 4d). On day 14, cross-linked MatriDerm subsequently showed a thick layer of 
confluescent dermal fibroblasts on cross-linked MatriDerm, covering the entire 
template. Non-cross-linked MatriDerm only displayed a centrally confluent layer at 
day 14. Cell morphology of the dermal fibroblasts was not affected in cross-linked 
MatriDerm as the cells displayed similar healthy characteristics to the cells seeded 
onto non-cross-linked MatriDerm. The results from the scanning electron microscopy 
images were consistent with cell quantification, distribution and migration 
measurements. 
 
3.3 In-vivo analysis 
3.3.1 Graft take 
Similar graft take rate was measured in both cross-linked and non-cross-linked 
MatriDerm. At respectively 86% and 78% graft take for non-cross-linked and cross-
linked MatriDerm, no significant difference between take was observed (Fig. 5a). 
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3.3.2 Wound contraction 
Both cross-linked and non-cross-linked MatriDerm displayed similar wound 
contraction rate. No significant difference was found overall between cross-linked 
and non-cross-linked wound contraction or at any individual time point or at any rate 
(Fig. 5b). Wound contraction rates increased at day 7 for both cross-linked and non-
cross-linked MatriDerm, stabilising on day 21. Wounds in cross-linked and non-
crosslinked models contracted in total by 50.7% and 49.4%, respectively, at day 28. 
 
3.3.2 In-vivo host response and scaffold degradation 
Comparison of in-vivo scaffold degradation between cross-linked and non-cross-
linked displayed similar host response. Cell infiltration and local inflammation was 
not observed to be excessive in one scaffold over another. Despite similar host 
response, cross-linked MatriDerm showed a slower biodegradation in vivo. At day 7, 
both scaffolds displayed a similar intact and sturdy structure under a taken graft (Fig. 
5c), with cell infiltration observed between 20-40% for both scaffolds. At day 14 
however, non-cross-linked MatriDerm commenced to breakdown, fragmenting 
mainly centrally, with a considerable inflammatory response whilst cross-linked 
MatriDerm was grossly intact. In observation, 100% of the cross-linked MatriDerm 
scaffold was noted compared to 61% of the non-cross-linked MatriDerm scaffold. 
Host cell infiltration was observed to be higher centrally in non-cross-linked 
MatriDerm, ranging from 90-100% centrally to 50-60% peripherally. Cross-linked 
MatriDerm displayed a more evenly dispersed host cell infiltration between 40-60%. 
At day 28, cross-linked MatriDerm also showed signs of biodegradation, decreasing 
in size, whilst only remnants of non-cross-linked MatriDerm were found. 
Approximately 60% of cross-linked MatriDerm was noted remaining under the skin 
grafts, whilst approximately 8% of non-cross-linked was found. Non-cross-linked host 
cell infiltration was observed at 95-100% as the scaffold was fully absorbed and 
cross-linked MatriDerm at 95-100% centrally, where absorbed, but 60-70% 
peripherally, where fragments of the scaffold were still visible.  
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3.3.3 Angiogenesis  
Due to a variance in degradation rate between the scaffolds, non-cross-linked 
displayed angiogenesis earlier than cross-linked MatriDerm. Non-cross-linked 
MatriDerm was observed to have more neovascularization compared to cross-linked 
MatriDerm at day 14. Moreover, cross-linked MatriDerm subsequently displayed 
more angiogenesis at day 28. Overall, cross-linked MatriDerm was observed to 
display a greater amount of vessel formation than non-cross-linked MatriDerm. 
 
4.0 Discussion 
Ideally, dermal templates should biodegrade gradually whilst promoting tissue 
regeneration at a similar speed to restore skin structures and functions to form 
healthy scar tissue. Many commercial dermal substitutes are available with 
differences in components, biological and mechanical properties, and cross-linking 
status, attempting to reach such an ideal composition. Optimising scaffold features 
including biostability and mechanical properties are therefore important in using 
dermal template for treating deep burns and minimizing wound contraction and 
scarring. 
The study found that chemically cross-linking MatriDerm enhanced the scaffold’s 
strength and stability, pro-longing its durability in both in-vitro and in-vivo. Its 
increased strength and the effect on reducing the biodegradability rate over time, 
allowed for an extended exposure of the collagen-elastin matrix and its constructive 
scarring properties in a healing wound.  
Cross-linking with glutaraldehyde has been a widely used technique in various tissue 
engineering applications, increasing protein stability. It is a technique that is used by 
Integra, the first artificial dermal template, still clinically used today. However, 
previous studies show that chemical cross-linking with glutaraldehyde has been the 
source for contradictory results, predominantly focused on cytotoxicity.[22-24] Some 
studies say that chemical cross-linking with glutaraldehyde is safe to use in 
decreased concentrations (<8%).[12] In this study, we did not find any evidence of 
adverse effects of the proposed cytotoxicity. In-vitro experiments with human dermal 
fibroblasts demonstrated increased proliferation of healthy cells on cross-linked 
MatriDerm and in-vivo results demonstrated similar graft take rates with increased 
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angiogenesis and no increased inflammatory response. Cross-linking MatriDerm 
developed a macroscopically sturdier, less fragile scaffold, making it easier to 
handle, confirmed with tensile testing. By increasing the scaffold rigidity, we found 
enhanced cell proliferation and migration of dermal fibroblasts throughout the 
template. In previous reports, human dermal fibroblasts are known to be adhesive 
and be favourable with rigid surface.[25] However, it has also been shown that on 
more rigid environments, fibroblasts tend to differentiate into myofibroblasts, the 
main contributor of contraction [26, 27]. Despite increased tensile strength of cross-
linked MatriDerm and an increased amount of fibroblasts due to increased 
proliferation following seeding, in-vitro experiments showed no evidence of increased 
contraction of the scaffold itself. Contraction of cross-linked MatriDerm was present 
but found to be independent of the presence of human dermal fibroblasts and shown 
to be significantly less than non-cross-linked MatriDerm.  
By enhancing physiochemical strength through cross-linking, pore size and porosity 
were affected. In the quest for an ideal dermal template, investigation into the ideal 
pore size has been complicated by the growing possibilities of biomaterials and 
building techniques, each with its own effect on cell interaction.[28, 29] Furthermore, 
specific cells require different pore size for optimal cell attachment, growth and 
motility.[30] In poly(L-lactic acid) and poly(L-lactic-co-glycolic acid) scaffolds pore 
sizes smaller than 160µm have been reported to be optimal for attachment of human 
skin fibroblasts.[31] In a study with collagen-glycosaminoglycan scaffold cross-linked 
with glutaraldehyde grafted in guinea pigs, the optimal pore size was suggested to 
be between 20 to 125 µm, however, requiring autologous cells seeding prior to 
implantation.[32] In fact, a recent study examining the effects using an alternative 
chemical cross-linking method, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride cross-linking, on collagen scaffolds, showed the effect of pore size to 
be more advantageous if not too enlarged, as a larger pore size promotes further 
myofibroblast differentiation and more foreign body giant cells.[33] In the present 
study, pore size was measured approximately 26.5 µm for non-crosslinked 
MatriDerm and 25 µm for cross-linked MatriDerm. The significant decrease in pore 
size and porosity after cross-linking, did not inhibit cell migration or proliferation of 
the human dermal fibroblasts on cross-linked MatriDerm. Interestingly, increased 
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proliferation and more disperse cell migration was found on cross-linked MatriDerm 
with reduced pore size and porosity. These findings may be attributed to higher 
surface wettability of exposure of protein on the surface, facilitating cell migration 
through the pores. SEM analysis of seeded dermal fibroblasts on day 14 revealed 
long process extensions of cells that linked to the underlying scaffolds and to 
neighbouring cells, indicating strong cell adhesion with the underlying substrate via 
focal contacts and good overall biocompatibility before and after cross-linking. SEM 
analysis also confirmed that cross-linked MatriDerm is seemingly more favourable 
for supporting formation of a confluent layer of dermal fibroblasts over 14 days, while 
maintaining the integrity of the scaffold.  
By cross-linking MatriDerm, it’s matrix’s durability was enhanced without impeding 
on cell integration and health, increasing the presence of elastin during the wound 
healing period and thereby maintaining its supportive influence during scar 
maturation for a longer period of time. Elastin has been shown to have an effect on 
cell differentiation[34], native elastin production[35] and angiogenesis[21], promoting 
healthy scar formation. Alpha-elastin reduces the differentiation of fibroblasts into 
myofibroblast.[34] Together with the increased presence of native elastin and the 
reduction of myofibroblasts, it is expected to form a more pliable scar. Furthermore, 
elastin in a collagen-elastin matrix, has shown to enhance the architecture of scar 
tissue, with a more organized formation of collagen, to closer relate to normal skin 
properties.[36] By stabilising the collagen-elastin matrix, its extended presence 
during the proliferation phase of wound healing will improve scar quality. In this 
study, we have found that cross-linked MatriDerm was present and intact for a longer 
period of time in-vivo. After 2 weeks, cross-linked MatriDerm was still intact whereas 
non-cross-linked MatriDerm was almost completely biodegraded, allowing it to 
extend further into the proliferation phase of wound healing. Increased angiogenesis 
was also observed in presence of cross-linked MatriDerm, potentially relating to a 
pro-longed presence of elastin. No excessive collagen formation or inflammatory 
response was noted in cross-linked MatriDerm which is supported by similar graft 
take data between both cross-linked and non-cross-linked MatriDerm. Although no 
significant evidence was found in terms of wound contraction in the murine model, 
the result is likely due to the mechanisms of wound healing in mice. Murine skin 
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heals by contraction, due to the presence of panniculus carnosus beneath the skin, 
whereas human skin heals by re-epithelization, making skin contraction studies 
imprecise in murine models.[37, 38] Further skin contraction experimentation 
comparing non-crosslinked and cross-linked MatriDerm, would be more suitable in a 
porcine model.  
The potential for a stronger collagen-elastin dermal template is not just limited to the 
extended exposure of elastin in a healing wound but further in the field of cultured 
epithelial autografts. By creating a scaffold that is rigid enough for dermal fibroblast 
and keratinocyts to proliferate on in an in-vitro environment, autologous cells can be 
grown in-lab on a rigid base forming an autologous cultured epithelial autograft, 
enhancing its future prospective use on the reconstructive ladder.  
 
5.0 Conclusion 
In this study we found that cross-linking a collagen-elastin matrix with glutaraldehyde 
increased the scaffold’s strength and reduced its biodegradation rate. Exposure to 
human dermal fibroblasts in an in-vitro environment demonstrated positive 
compatibility and reduced contraction of the scaffold.  Without affecting wound 
healing or graft take, cross-linked MatriDerm was found to have a pro-longed 
durability in a healing wound, causing no excessive scar formation. Despite no 
significant difference found wound contraction, the extended exposure of cross-
linked MatriDerm in a wound could potentially have beneficial effects on scar tissue, 
promoting the formation of a more pliable, healthy scar. As cross-linked MatriDerm 
presents a more stable 3-dimensional matrix, its potential use in skin tissue 
engineering promises a great future.  
 
 
For all figures and graphs, please see the following three pages (pgs. 42-44)  
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Figure 1a. Tensile modulus for non-cross-linked and cross-linked MatriDerm. p-value=0.012E-1. Figure 1b. Accumulated protein release 
from cross-linked and non-cross-linked MatriDerm over 35 days.  p-value=0.031E-3. Error bars not visible due to small variation. 
** 
*** 
2a        Non-cross-linked MatriDerm                              Cross-linked MatriDerm 
Figure 2a. Scanning electron microscopy images of non-cross-linked and cross-linked MatriDerm, scale bar = 100µm. Figure 
2b. Average pore size of non-cross-linked and cross-linked MatriDerm. p-value=0.024. Figure 2c. Porosity of non-cross-linked 
MatriDerm compared to cross-linked MatriDerm. p-value=0.012E-13. Figure 2d. Transverse sections of H&E fixed non-cross-
linked and cross-linked MatriDerm prior to binary conversion, scale bar = 200 µm of and 100 µm in higher resolution. 
 
 2d      Non-cross-linked MatriDerm                          Cross-linked MatriDerm 
*** * 
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Figure 3a. Macroscopic images of non-cross-linked (NCLM) and cross-linked MatriDerm (CLM) seeded with human dermal 
fibroblasts in a cell cultured environment on day 14. Figure 3b. Diameter (mm) of non-cross-linked and cross-linked MatriDerm seeded 
with human dermal fibroblasts on day 0, 1 (p-value=0.024E-2), and 14 (p-value=0.018E-3). Figure 3c. Diameter (mm) of non-cross-linked 
MatriDerm without dermal fibroblasts and seeded with dermal fibroblasts on day 0,1, and 14. Figure 3d. Diameter (mm) of cross-linked 
MatriDerm without dermal fibroblasts and seeded with dermal fibroblasts on day 0, 1 and 14. NOTE: Y-axis of images 3 b, c, and d 
commence at 4mm (as the graphs become illegible if commenced at 0mm). 
 
3a 
     
 
 
 
    NCLM 
 
 
 
 
 
      CLM 
 
*** 
Figure 4a. Cell quantification of non-cross-linked and cross-linked MatriDerm on day 1 and day 14. p-value=0.047 for day 14. Figure 4b. 
Pattern of distribution of dermal fibroblasts in non-cross-linked and cross-linked MatriDerm on day 1 incl. schematic drawing top left corner 
of scaffold cross-sections related to slide number. Figure 4c. Pattern of distribution of dermal fibroblasts in non-cross-linked and cross-
linked MatriDerm on day 14. Figure 4d. Scanning electron microscopy of non-cross-linked (NCLM) and cross-linked MatriDerm 
(CLM) seeded with human dermal fibroblasts on day 1 and 14, scale bar = 500 µm. 
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Day 7           Day 14                     Day 28 
5c 
Figure 5a. Graft take (%) of non-cross-linked and cross-linked MatriDerm in in-vivo analysis. Figure 5b. Wound contraction of non-cross-
linked and cross-linked MatriDerm on days 3,5,7,10,14,21,28. Figure 5c. H&E stained cross-linked and non-cross-linked MatriDerm on 
day 7, 14 and, 28. Scaffolds indicated by dotted line and arrows, scale bar = 100 µm 
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Reagent		 	 	 	 	 	 	 	 Supplier	
1,1,1,3,3,3-hexafluoro-2-propanol	(HFP)		 	 	 	 Sigma-Aldrich	
Acetic	acid,	glacial		 	 	 	 	 	 	 Sigma-Aldrich	
Acid	Fuchsin		 	 	 	 	 	 	 	 Acros	Organics	
Agarose	(Molecular	Biology	Grade)		 	 	 	 	 Vivantis	
Ammonium	iron	(III)	sulphate	dodecahydrate		 	 	 Sigma-Aldrich	
Atrauman		 	 	 	 	 	 	 	 Hartmann	
Betadine	solution		 	 	 	 	 	 	 Sanofi-Aventis	
Bicinchonic	acid	assay	(Pierce	BCA	assay)	 	 	 	 ThermoFisher	Scientific	
Bouin's	Fluid		 	 	 	 	 	 	 	 Australian	Biostain	
Bovine	neck	ligament	elastin,	soluble		 	 	 	 Sigma-Aldrich	
Bovine	serum	albumin,	powder		 	 	 	 	 Sigma-Aldrich	
Carprofen		 	 	 	 	 	 	 	 Rimadyl	
Celestine	Blue		 	 	 	 	 	 	 Sigma-Aldrich	
Chloroform		 	 	 	 	 	 	 	 Sigma-Aldrich	
Dimethyl	sulfoxide	(DMSO)		 	 	 	 	 	 Sigma-Aldrich	
Dulbecco	modified	eagle's	medium	(DMEM)		 	 	 Sigma-Aldrich	
Eosin	yellowish		 	 	 	 	 	 	 VWR	
Ethanol	(for	molecular	biology),	100	%		 	 	 	 Sigma-Aldrich	
Ethanol,	100	%		 	 	 	 	 	 	 Sigma-Aldrich	 	
Fetal	bovine	serum	(FBS)		 	 	 	 	 	 Sigma-Aldrich	
Glutamine		 	 	 	 	 	 	 	 Sigma-Aldrich	
Glutaraldehyde,	25	%,	EM	grade		 	 	 	 	 ProSciTech	
Glutaraldehyde,	25	%,	Grade	1		 	 	 	 	 Sigma-Aldrich	
Glycerin		 	 	 	 	 	 	 	 Sigma-Aldrich	
Glycine		 	 	 	 	 	 	 	 Ajax	Finechem	
Harris'	Haematoxylin,	Concord	Modified	Australian			 	 Biostain	
Hexamethyldisilazane	(HMDS)		 	 	 	 	 Sigma-Aldrich	
Hydrochloric	acid	(HCl)		 	 	 	 	 	 Sigma-Aldrich	
Hydrogen	peroxide,	30	%	(w/v)		 	 	 	 	 Sigma-Aldrich	
HyperLadder	100bp	(IV)		 	 	 	 	 	 Bioline	
IDRT		 	 	 	 	 	 	 	 	 IDRT	Life	Sciences	
Isopropanol	(for	cell	cryopreservation)	 	 	 	 	VWR	International	
IV3000		 	 	 	 	 	 	 	 Smith	&	Nephew	
L-Glutamine		 	 	 	 	 	 	 	 Sigma-Aldrich	
Light	Green	SF	Yellowish		 	 	 	 	 	 Acros	Organics	
MangoTaq	colourless	reaction	buffer,	5×		 	 	 	 Bioline	
MatriDerm		 	 	 	 	 	 	 	 MedSkin	Solutions	
Neutral-buffered	formalin	solution,	10	%	(v/v)		 	 	 Sigma-Aldrich	
OsO4,	4	%	aqueous	solution		 	 	 	 	 	 ProSciTech	
Paraformaldehyde,	16	%	aqueous	solution		 	 	 	 ProSciTech	
Penicillin-Streptomycin-Neomycin	solution		 	 	 	 Sigma-Aldrich	
Phosphate	buffered	saline	(PBS)		 	 	 	 	 ThermoFisher	Scientific	
Phosphotungstic	acid	hydrate		 	 	 	 	 Acros	Organics	
Punch	biopsy,	8	mm	diameter		 	 	 	 	 Kai	Medical	
Saline,	sterile		 	 	 	 	 	 	 	 Astra	Zeneca	
Sodium	acetate		 	 	 	 	 	 	 Sigma-Aldrich	
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Sodium	cacodylate	trihydrate		 	 	 	 	 Sigma-Aldrich	
Sodium	Citrate		 	 	 	 	 	 	 Sigma-Aldrich	
Sulphuric	acid			 	 	 	 	 	 	 Ajax	Finechem	
Triton	X-100		 	 	 	 	 	 	 	 Sigma-Aldrich	
Trypan	Blue	solution,	0.4	%		 	 	 	 	 	 Sigma-Aldrich	
Trypsin-EDTA	solution,	0.25	%		 	 	 	 	 Sigma-Aldrich	
Visitrak		 	 	 	 	 	 	 	 Smith	&	Nephew	
Ilium	Xylazil-100	(xylazine)		 	 	 	 	 	 Troy	Laboratories	
Xylene		 	 	 	 	 	 	 	 Point	of	Care	Diagnostics	
Xylidine	Ponceau		 	 	 	 	 	 	 Acros	Organics 
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Chapter 3. Discussion  
Burn injury remains a common and devastating injury to human kind. Whilst mortality 
rate has been dwindling and it is now possible to survive even a severe burn injury, 
the long term quality of life for these survivors is greatly impacted by severe 
scarring[1, 2], a direct consequence of losing the physiology of the 3D architecture of 
the human dermis.[3] Replacing the physiologic human dermis will ultimately rely on 
the body’s ability to reconstitute its 3D architecture based on implanted dermal 
templates.[3, 4] 
 
An ideal artificial dermal template for severe burn management would contain all 
essential and natural components of normal human skin and functionally promote 
complete regeneration of full-thickness wounds into physiologic normal skin and 
prevent scarring. Although the field of skin tissue engineering is just over 40 years 
old, there are still many questions to be answered and advances to be made to 
create such an ideal solution.[4, 5]  
 
Protein-based dermal templates can be produced as cross linked or non-cross linked 
constructs that display different biostability, biodegradation rate and mechanical 
properties.[6] In this study, we have taken a step to examine the potential impact of 
those different properties aiming to further optimize the dermal template and its 
performance in wound healing. Although many commercial dermal substitutes of 
different cross-linking status, such as Integra and MatriDerm, are available, each of 
them has unique features in components, structure and thickness. Determined by 
the scaffold’s unique component elastin, MatriDerm was used as the study material 
and enhanced to increase its biostability and mechanical strength by cross linking, 
further defining any potential benefit in essential quality outcomes such as strength, 
stability, cell infiltration and biodegradation. Combining one of the well-established 
methods of cross-linking[7] with a newer dermal substitute enables us to create a 
more stable and durable dermal collagen-elastin template that showed positive 
effects on cell infiltration in-vitro, dermal repair, and angiogenesis without inducing 
negative influences on graft take or host response.  
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Chemical cross-linking of natural proteins has been well established with 
glutaraldehyde, despite contradictory evidence concerning cytotoxicity in-vitro.[7-9] 
In this study, no evidence of the proposed cytotoxicity in-vitro or in-vivo was found. 
Whilst other chemical cross-linking materials have been identified such as EDC and 
poly(carboxylic acids), to date no green alternative for cross-linking has been 
developed.[8] In this study the choice for cross-linking with glutaraldehyde was 
based on the safe and ongoing use of Integra, also cross-linked by glutaraldehyde. 
As both the collagen-elastin matrix and the cross-linking method are commonly used 
in separate commercially available products, the combination of both could have the 
potential for a further enhanced dermal substitute. 
 
The murine model study demonstrated cross-linked collagen-elastin template to 
have suitable biocompatibility, showing a comparable graft take and a non-
aggressive host response compared to non-cross-linked MatriDerm. The core 
function of dermal substitutes is to ultimately promote wound healing, skin 
regeneration and prevent scarring. Long-term analysis of outcomes such as 
contraction or other indicators of scarring were limited due to the animal model type 
used in the study and will be undertaken in future investigations. Further research 
will be aimed towards closely mimicking the human wound healing in a more 
advanced animal model. The core purpose of dermal substitutes is to improve scar 
tissue formation without affecting wound healing. The murine model study has 
demonstrated that wound healing is not affected by cross-linking. In this in vivo study 
wound contraction and scar tissue formation cannot be accurately assessed as 
murine and human skin wound heals differently due to anatomical and mechanical 
differences.[10, 11] The ability to perform split skin grafting in murine models is 
similarly limited, resulting in full-thickness grafting of autologous murine skin in our 
study. A porcine model will be the advanced model to further examination of the 
potential of a cross-linked collagen-elastin template on wound contraction and 
scarring, as porcine skin has been shown to be histologically more human skin alike 
and porcine skin wound heals by re-epithelization, similar to human skin allowing 
long-term analysis of outcomes.[10] However, these costly investigations in large 
animal models were outside the scope of this study of masters of philosophy. Ideally, 
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once the safety and efficacy of cross-linked collagen-elastin matrix can be shown in 
a future porcine model study, human clinical trials would be indicated. This murine 
study represents the essential first step to enable further research, proving the 
principle of cross-linking the collagen-elastin template, MatriDerm, and thereby 
increasing its stability without negative biological effects.  
 
By strengthening a collagen-elastin template, the potential for its use has been 
further amplified into the field of skin tissue engineering. Shortly after Yannas and 
Burke developed the first collagen-based artificial dermis, using glutaraldehyde to 
increase its stability, Rheinwald and Green were the first to culture human 
keratinocytes and became known as the pioneers of skin tissue engineering, by 
culturing keratinocytes into a functioning epidermis.[12, 13] The concept of cultured 
epithelial autografts was created. The first clinical trials in 1981[14, 15], at the same 
time as the first clinical trials of Integra, showed promise, commercializing the 
product as EpiCel in 1988.[15] However, the lack of a dermal elements in full-
thickness burns, essential for wound healing, proved to be a limitation of the cultured 
epithelial autografts.[16, 17] Cuono designed a method to overcome this by laying 
the cultured epithelial autograft over a well vascularized allogenic dermis, 
demonstrating the importance of dermal components.[18, 19] Eventually, in 1998 the 
concept combining Integra and a cultured epithelial autograft was created.[20] 
Unfortunately, the combination of the products did not work as well as expected, 
found to be due to the lack of a basement membrane, the connection present in 
human skin as interphase of the dermis and epidermis.[21, 22] It is now understood 
that the basement membrane is formed when both prominent skin cells are cultured 
together, dermal fibroblasts and keratinocytes.[23]  Advances in the field of skin 
tissue engineering progressed further, aiming to increase the complexity of skin 
substitutes, to resemble native skin more closely. Boyce et al. successfully showed 
the advantages of culturing dermal fibroblasts and keratinocytes on a collagen based 
substrate[24-26], developing a basement membrane. The now commercially 
available PermaDerm is based on that concept.[5, 27] However, there is still lack of 
resemblance to native skin complexities and limitations in vascularization.[4] 
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Currently, research into the incorporation of stem cells, melanocytes, hair follicles, 
blood and lymphatic capillaries are all contributing to raising the complexity.[3, 28-32]     
 
With the progress of raising complexity of tissue engineered skin, the base that all 
skin components and contents rest on has become essential. In skin tissue 
engineering, current bases are collagen-based scaffolds, lacking one of the most 
essential dermal components, elastin.  The inclusion of elastin, a key natural matrix 
protein in dermal substitute in skin could improve the structural and biological 
features of artificial dermis. Physiologically, human skin’s support base is its 
extracellular matrix, a scaffold composed mainly of collagen, intertwined with elastin, 
an integral structural and mechanical component.[33] This effective base gives skin 
its natural strength and elasticity, supporting all elements of the dynamic structure. 
By using a collagen-elastin scaffold as a base for in-vitro skin tissue engineering, 
scaffold resemblance to native skin architecture would be more natural. As it was 
previously proven, the presence of elastin assists in neovascularization and promote 
a more natural regeneration of the human dermis.[34, 35] Murine keratinocytes and 
endothelial cells have been shown to proliferate on collagen-elastin templates in the 
past, showing a potential [36], as has it been shown to function as an epidermal 
carrier for keratinocytes and melanocytes.[37] However, the current commercial 
elastin containing template could not fulfil the role as a template for in vitro skin 
tissue engineering because it lacks the required biological and mechanical strength, 
limiting its use to a carrier function.[37] Data from this study has shown the potential 
of its use in this upcoming field by cross linking to stabilize its construct; improving its 
3D architecture allowing it to play a role in in-vitro dermal skin tissue engineering as 
such, have the strength to supporting a complex, dynamic environment. In this study, 
the evidence of the positive effect of increased rigidity on cell-scaffold interaction, 
demonstrated its potential and indicating a further need for investigation into the 
collagen-elastin’s in-vitro skin engineering role. The previously suggested further 
research into the advantages of cross-linked collagen-elastin matrixes should not be 
limited to in-vivo experimentation alone, utilizing a porcine model. Further in-vitro 
research should cultivate and develop the concept of a collagen-elastin matrix and 
its role in in-vitro skin tissue engineering. 
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